---
document_datetime: 2024-05-17 12:32:40
document_pages: 76
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/retsevmo-h-c-005375-ii-0021-epar-assessment-report-extension_en.pdf
document_name: retsevmo-h-c-005375-ii-0021-epar-assessment-report-extension_en.pdf
version: success
processing_time: 108.3478858
conversion_datetime: 2025-12-21 23:10:39.195776
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 January 2023 EMA/60663/2024 Committee for Medicinal Products for Human Use (CHMP)

## CHMP extension of indication variation assessment report

Invented name: Retsevmo

International non-proprietary name: selpercatinib

Procedure No. EMEA/H/C/005375/II/0021

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                | .............................................. 6                                                           |
|---------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation .................................................................................................. | 6                                                                                                          |
| 1.2. Steps taken for the assessment of the product                                                                        | ......................................................... 6                                                |
| 2. Scientific discussion                                                                                                  | ................................................................................ 7                         |
| 2.1.1. Problem statement                                                                                                  | ............................................................................................ 7             |
| 2.1.2. About the product                                                                                                  | .............................................................................................. 9           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                 | advice ...... 10                                                                                           |
| 2.1.4. General comments on compliance with GCP                                                                            | ........................................................ 10                                                |
| 2.2. Non-clinical aspects                                                                                                 | ............................................................................................ 11            |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                          | ......................................................... 11                                               |
| 2.2.2. Discussion and conclusion on non-clinical aspects                                                                  | ................................................ 14                                                        |
| 2.3. Clinical aspects                                                                                                     | .................................................................................................. 14      |
| 2.3.1. Introduction                                                                                                       | .................................................................................................... 14    |
| 2.3.2. Pharmacokinetics                                                                                                   | ............................................................................................. 15           |
| 2.3.3. Pharmacodynamics                                                                                                   | .......................................................................................... 18              |
| 2.3.4. Discussion on clinical pharmacology                                                                                | ................................................................... 18                                     |
| 2.3.5. Conclusions on clinical pharmacology                                                                               | ................................................................. 19                                       |
| 2.4. Clinical efficacy                                                                                                    | .................................................................................................. 19      |
| 2.4.1. Main study(ies)                                                                                                    | ............................................................................................... 19         |
| 2.4.2. Discussion on clinical efficacy ............................................................................       | 54                                                                                                         |
| 2.4.3. Conclusions on the clinical efficacy .....................................................................         | 57                                                                                                         |
| 2.5. Clinical safety                                                                                                      | .................................................................................................... 57    |
| 2.5.1. Discussion on clinical safety ..............................................................................       | 67                                                                                                         |
| 2.5.2. Conclusions on clinical safety ............................................................................        | 68                                                                                                         |
| 2.5.3. PSUR cycle                                                                                                         | ..................................................................................................... 68   |
| 2.6. Risk management plan                                                                                                 | ........................................................................................ 68                |
| 2.7. Update of the Product information ........................................................................           | 70                                                                                                         |
| 2.7.1. User consultation                                                                                                  | ............................................................................................. 70           |
| 3. Benefit-Risk Balance ..............................................................................                    | 70                                                                                                         |
| 3.1. Therapeutic Context                                                                                                  | ........................................................................................... 70             |
| 3.1.1. Disease or condition                                                                                               | ......................................................................................... 70               |
| 3.1.2. Available therapies and unmet medical need                                                                         | ....................................................... 71                                                 |
| 3.1.3. Main clinical studies                                                                                              | ......................................................................................... 71               |
| 3.2. Favourable effects                                                                                                   | .............................................................................................. 71          |
| 3.3. Uncertainties and limitations about favourable effects                                                               | ............................................. 71                                                           |
| 3.4. Unfavourable effects                                                                                                 | ........................................................................................... 72             |
| 3.5. Uncertainties and limitations about unfavourable effects                                                             | ......................................... 72                                                               |
| 3.6. Effects Table                                                                                                        | ...................................................................................................... 73  |
| 3.7. Benefit-risk assessment and discussion                                                                               | 73                                                                                                         |
| .................................................................                                                         |                                                                                                            |
| 3.7.2. Balance of benefits and risks                                                                                      | 74                                                                                                         |
| ............................................................................. balance                                     | ........................................... 74                                                             |
| 3.7.3. Additional considerations on the benefit-risk 3.8. Conclusions                                                     | ....................................................................................................... 75 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations ................................................................................. 75

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AE      | adverse event                                              |
|---------|------------------------------------------------------------|
| AESI    | adverse event of special interest                          |
| ALT     | alanine aminotransferase                                   |
| AST     | aspartate aminotransferase                                 |
| ATC     | anaplastic thyroid cancer                                  |
| AUC0-24 | area under the concentration-time curve from 0 to 24 hours |
| BID     | twice daily                                                |
| CBR     | clinical benefit rate                                      |
| CSR     | clinical study report                                      |
| CI      | confidence interval                                        |
| Cmax    | maximum drug concentration                                 |
| CR      | complete response                                          |
| DTC     | differentiated thyroid cancer                              |
| DOR     | duration of response                                       |
| ECG     | Electrocardiogram                                          |
| ECOG    | Eastern Cooperative Oncology Group                         |
| EMA     | European Medicines Agency                                  |
| EU      | European Union                                             |
| FTC     | follicular thyroid cancer                                  |
| IRC     | Independent Review Committee                               |
| MKI     | multikinase inhibitor                                      |
| MTC     | medullary thyroid cancer                                   |
| NSCLC   | non-small cell lung cancer                                 |
| ORR     | objective response rate                                    |
| OS      | overall survival                                           |
| PBT     | PBT (persistent and bioaccumulative and toxic)             |
| PD      | progressive disease                                        |
| PDTC    | poorly differentiated thyroid carcinoma                    |
| PFS     | progression-free survival                                  |

<div style=\"page-break-after: always\"></div>

| PK             | Pharmacokinetic(s)                                                   |
|----------------|----------------------------------------------------------------------|
| PR             | partial response                                                     |
| PT             | preferred term                                                       |
| PTC            | papillary thyroid cancer                                             |
| QD             | Once daily                                                           |
| RAI            | radioactive iodine                                                   |
| RECIST         | Response Evaluation Criteria in Solid Tumors                         |
| RET            | REarranged during Transfection                                       |
| SAE            | serious adverse event                                                |
| SmPC           | Summary of Product Characteristics                                   |
| TEAE           | treatment-emergent adverse event)                                    |
| TC             | thyroid cancer                                                       |
| TC:TrtSys      | Patients Previously Treated with systemic therapy                    |
| TC:TrtSysNaïve | Patients Not Previously Treated with systemic therapy other than RAI |
| TESAE          | treatment-emergent SAE                                               |
| vPBT           | Very PBT (persistent and bioaccumulative and toxic)                  |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Eli Lilly Nederland B.V. submitted to the European Medicines Agency on 30 November 2022 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer in the first-line setting for RETSEVMO based on interim data from studies LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121; LIBRETTO-001 is an openlabel, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumors. LIBRETTO-121 is a Phase 1/2 study of selpercatinib in paediatric patients with advanced RETaltered solid or primary central nervous system tumours. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision PIP decision number: P/0133/2023 on the agreement of a paediatric investigation plan (PIP).

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 30 November 2022 |
| Start of procedure:                                  | 31 December 2022 |
| CHMP Rapporteur Assessment Report                    | 28 February 2023 |
| PRAC Rapporteur Assessment Report                    | 2 March 2023     |
| PRAC members comments                                | 8 March 2023     |
| PRAC Outcome                                         | 16 March 2023    |
| CHMP members comments                                | 20 March 2023    |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 23 March 2023    |
| Request for supplementary information (RSI)          | 30 March 2023    |
| CHMP Rapporteur Assessment Report                    | 26 June 2023     |
| PRAC Rapporteur Assessment Report                    | 27 June 2023     |
| PRAC Outcome                                         | 6 July 2023      |
| CHMP members comments                                | 10 July 2023     |
| Updated CHMP Rapporteur Assessment Report            | 17 July 2023     |
| Request for supplementary information (RSI)          | 20 July 2023     |
| CHMP Rapporteur Assessment Report                    | 11 October 2023  |
| PRAC Rapporteur Assessment Report                    | 16 October 2023  |
| PRAC Outcome                                         | 26 October 2023  |
| CHMP members comments                                | 27 October 2023  |
| Updated CHMP Rapporteur Assessment Report            | 31 October 2023  |
| Request for supplementary information (RSI)          | 9 November 2023  |
| CHMP Rapporteur Assessment Report                    | 20 December 2023 |
| CHMP members comments                                | 15 January 2024  |
| Updated CHMP Rapporteur Assessment Report            | 19 January 2024  |
| Opinion                                              | 25 January 2024  |

## 2. Scientific discussion

## 2.1.1. Problem statement

## Disease or condition

The MAH is seeking an extension of indication for selpercatinib as monotherapy for adults with advanced RET fusion-positive thyroid cancer without prior standard first line therapy (i.e. first-line setting).

<div style=\"page-break-after: always\"></div>

Additionally, the MAH is seeking an extension of indication for selpercatinib as monotherapy for adolescents (≥ 12 years of age) with advanced RET fusion-positive thyroid cancer (i.e. first and later line).

## Epidemiology

The thyroid follicle-derived, differentiated cancers (papillary thyroid cancer [PTC] and follicular thyroid cancer [FTC]) are the most common thyroid cancers, accounting for 80% to 85% and 10% to 15% of all thyroid cancer cases, respectively (Aboelnaga and Ahmed 2015). Poorly differentiated subtypes [PDTC] and anaplastic thyroid cancer [ATC]) account for 5% to 10% of thyroid cancers and are characterized by less differentiated histologic features and more aggressive clinical behaviour than the differentiated subtypes (Landa 2016).

RET gene fusions have been identified in approximately 6% to 9% of PTCs and approximately 6% of PDTCs (Fusco 1987; Agrawal 2013; Cancer Genome Atlas Research 2014; Kato 2017; Landa 2016). In contrast to PTC and PDTC, neither FTC nor ATC are frequently associated with RET gene fusions. Most differentiated thyroid cancers, including PTC, are largely asymptomatic, treatable tumours with an excellent prognosis after surgical resection and radioiodine therapy (Pacini et al., 2012).

In Europe, an estimated 53,000 patients developed thyroid cancer in 2012.  Assuming 84% of those cases were PTC (44,520), and assuming RET- fusion gene alterations, according to more recent data (Santoro 2020), are present in 11% of PTC patients the incidence of new cases of RET- fusion positive PTC was approximately 4900 per year (ENRC 2019; Roskoski and Sadeghi-Nejad 2018).

Although extremely rare, the most common form of thyroid cancer in children is PTC. In addition, children with differentiated thyroid cancer have a higher prevalence of gene rearrangements (Segni et al. 2017). Thyroid carcinomas occurring in children carry a unique set of clinical, pathologic, and molecular characteristics.

## Biologic features

Genetic alterations in the RET gene have been implicated in the pathogenesis of several human cancers. RET can become oncogenically activated through two primary mechanisms: 1) chromosomal rearrangements that fuse the RET kinase domain with a partner protein dimerization domain (e.g., Coiled-coil domain-containing protein 6 (CCDC6)/papillary thyroid cancer-1 (PTC1), Kinesin Family Member 5B (KIF5B), NCOA4/PTC3), producing hybrid proteins that endow the kinase with ligandindependent, constitutive activity; and 2) point mutations that directly or indirectly activate the kinase (Drilon et al. 2018).

## Clinical presentation, diagnosis and stage/prognosis

The clinical course of RET fusion-positive PTC is heterogeneous, varying from some tumours being cured by surgical resection to aggressive cancers associated with metastases and high mortality. Recurrent disease is treated with reoperation and/or radioactive iodine therapy. However, these treatments are associated with significant morbidity and are often not curative.

In comparison to adults, children more often present with aggressive, advanced stage disease. This is at least in part due to the underlying biologic and molecular differences between paediatric and adult thyroid cancer. Specifically, papillary thyroid carcinoma (which accounts for approximately 90% of paediatric thyroid cancer) has a high rate of gene fusions (50-60%, compared to approximately 15%

<div style=\"page-break-after: always\"></div>

seen in adults) and are associated with more extensive extrathyroidal disease (Starenki and Park 2015).

The prognosis is favourable for the papillary and follicular subtypes of thyroid cancer, as they are slower-growing, indolent and rarely fatal cancers, as evidenced by the high 5-year relative survival in the EUROCARE-5 study (greater than 95% in PTC and 87% in follicular thyroid cancer (Dal Maso et al. 2017). In the US, the 5-year survival rate for metastatic PTC is 78% compared to 99% for localised cancer (ASCO 2019).

## Management

Patients with RET fusion-positive PTC or PDTC receive standard of care for their thyroid cancer subtype. Standard treatment options for PTC, include surgery and radioactive iodine (RAI) (Nguyen et al. 2015).  PDTC is less responsive to radioactive iodine than PTC. Paediatric patients with PTC are also treated with surgical resection and RAI therapy, although the specifics of RAI are somewhat different in this population (Paulson et al. 2019).

No systemic agents are approved specifically for patients with advanced RETfusion thyroid cancer.

Two available multikinase inhibitors (MKIs), sorafenib and lenvatinib, are approved for the treatment of unresectable, iodine-refractory differentiated thyroid cancer, irrespective of the presence or absence of a RET mutation.

## 2.1.2. About the product

Selpercatinib  is  an  inhibitor  of  the  rearranged  during  transfection  (RET)  receptor  tyrosine  kinase (including KIF5B-RET and CCDC6-RET).

RETSEVMO (Selpercatinib) was granted a CMA on 11 Feb 2021.

As of today the approved indications are 1) the treatment of advanced RET fusion-positive NSCLC in adult patients not previously treated with a RET inhibitor, 2) advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib and 3) advanced RET-mutant MTC in adult and pediatric patients 12 years of age and older.

The conditional MA was approved based on ORR and DOR observed in the ongoing Phase 1/2 study, LIBRETTO-001.

The presence of a RET gene fusion or mutation should be confirmed by a validated test prior to initiation of treatment with Retsevmo.

The recommended dose of Retsevmo based on body weight is:

-Less than 50 kg: 120 mg twice daily.

-50 kg or greater: 160 mg twice daily.

If  a  patient  vomits  or  misses  a  dose,  the  patient  should  be  instructed  to  take  the  next  dose  at  its scheduled time; an additional dose should not be taken.

Treatment should be continued until disease progression or unacceptable toxicity.

The applied indication is:

Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with:

-

advanced RET fusion-positive thyroid cancer

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Evaluation of clinical safety and efficacy of selpercatinib in patients with RET fusion-positive tissue is based on the analysis of interim data from LIBRETTO-001 (LOXORET- 17001; J2G-OX-JZJA) and LIBRETTO-121 Study. LIBRETTO-001 is a global, multicohort, open-label, phase 1/2 study in adult and adolescent with advanced RET-altered tumours. LIBRETTO-121 is a multicentre, open-label, Phase 1/2 study in paediatric patients with an advanced solid or primary central nervous system tumour harbouring, an activating RET alteration.

Table 1. Regulatory interactions in the EU for Retsevmo

| Date              | RegulatoryInteraction                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08 November 2019  | PIP Decision: Condition: Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms). A waiver was granted which applies to the paediatric population from birth to less than 6 months of age which applies to capsule, hard, age-appropriate dosage form, oral use, and on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible |
| Date              | RegulatoryInteraction                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                   | Indications: Treatment of adolescents with RET-mutant MTC who require systemic therapy, have progressed following prior treatment, and have no acceptable alternative treatment options. Treatment of paediatric patients with RET-altered, locally advanced or metastatic, solid tumours or primary CNS tumours                                                                                                                                                                               |
| 11 February 2021  | EC adoption of the positive decision for granting a conditional MA for second-line treatment of RET fusion-positive NSCLC, RET fusion-positive TC and RET-mutant MTC                                                                                                                                                                                                                                                                                                                           |
| 21 June 2022      | Approval of extension of indication to include first-line treatment of adults with advanced RET fusion-positive NSCLC not previously treated with a RET inhibitor                                                                                                                                                                                                                                                                                                                              |
| 02 September 2022 | Approval of extension of indication to include first-line treatment of adults and adolescents 12 years and older with advanced RET-mutant MTC                                                                                                                                                                                                                                                                                                                                                  |

Abbreviations: CNS = central nervous system; EC = European Commission; MA = marketing authorisation; MTC = medullary thyroid cancer; NSCLC = non-small cell lung cancer; PIP = paediatric investigation plan; RET = REarranged during Transfection; TC= thyroid cancer.

The 13 April 2023, a decision on the acceptance of a modification of an agreed PIP for selpercatinib has been issued.

## 2.1.4. General comments on compliance with GCP

The Applicant stated that clinical trials that support this use of selpercatinib were conducted in accordance with:

- 1) consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines for Biomedical Research Involving Human Subjects,
- 2) the International Conference on Harmonisation (ICH) Good Clinical Practices (GCP)

<div style=\"page-break-after: always\"></div>

Guideline (E6), and

- 3) applicable laws and regulations of the country or countries where a study is conducted.

The Applicant also stated that clinical trials conducted outside the European Union meet the ethical requirements of Directive 2001/20/EC4 GCP.

Table 2. Clinical studies contained in this application that were inspected by regulatory authorities

| Name                                                    | Agency Name(s)                                             | Begin Date   | End Date     | Observations?                             |
|---------------------------------------------------------|------------------------------------------------------------|--------------|--------------|-------------------------------------------|
| University of Texas MD Anderson Cancer Center - Subbiah | US FDA                                                     | 08-Jan- 2020 | 14-Jan- 2020 | No                                        |
| The Ohio State University - Shah                        | US FDA                                                     | 27-Jan- 2020 | 07-Feb- 2020 | Yes (1 Not Classified observation)        |
| MassachusettsGeneral Hospital - Wirth                   | US FDA                                                     | 30-Jan- 2020 | 10-Feb- 2020 | No                                        |
| Japan Affiliate                                         | Pharmaceuticals and Medical Devices Agency of Japan (PMDA) | 17-May- 2021 | 17-May- 2021 | No                                        |
| Medpace Singapore Pte Ltd                               | Health Sciences Authority (Singapore Regulatory Agency)    | 12-Jul- 2021 | 14-Jul- 2021 | Yes (2 Major, 3 Minor/Other Observations) |
| Korea Affiliate                                         | Korea Ministry of Food and Drug Safety (MFDS)              | 02-Sep- 2021 | 03-Sep- 2021 | Yes (1 Minor/Other Observation)           |

Abbreviation: N/A = not applicable; US FDA = United States Food and Drug Administration.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

## Prevalence of Currently Authorised Indications

Selpercatinib is currently authorised for patients with thyroid cancer (medullary, papillary, and other subtypes) and lung cancer (NSCLC subtype), specifically those that have activated RET through alterations of the RET gene such as fusions and mutations. Patients tested for gene alterations and only those positive can be dosed with selpercatinib.

<div style=\"page-break-after: always\"></div>

The prevalence of the indications for selpercatinib was derived from the prevalence of each cancer type in each EU member state using 3-year prevalence data (IARC, accessed 2022) and then refined for the frequency of the indicated cancer subtypes and the frequency of activated RET in that subtype. The 3year prevalence data was used instead of 1-year data because some patients may have been treated with selpercatinib longer than one year. Cancer prevalence was not adjusted for cancer stage or whether patients have received prior treatment with other cancer medicine or for use in only adults with the cancer, these assumptions will also result in conservatism in the PEC calculations.

Since the PECsurface water was greater than 0.01 µg∙L-1, a Phase II risk assessment has been conducted. Summary of the main study results are presented below.

Table 3. Summary of main study results

| Substance (INN/Invented Name): Selpercatinib / Retsevmo             | Substance (INN/Invented Name): Selpercatinib / Retsevmo   | Substance (INN/Invented Name): Selpercatinib / Retsevmo                                                        | Substance (INN/Invented Name): Selpercatinib / Retsevmo   |
|---------------------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| CAS-number : 152628-33-4                                            | CAS-number : 152628-33-4                                  | CAS-number : 152628-33-4                                                                                       | CAS-number : 152628-33-4                                  |
| PBT screening                                                       |                                                           | Result                                                                                                         | Conclusion                                                |
| Bioaccumulation potential- log K ow                                 | OECD107 …                                                 | log Kow = 1.30 at pH 5 log kow = 3.08 at pH 7 log kow = 3.45 at pH 9                                           | Potential PBT (N)                                         |
| PBT-assessment                                                      | PBT-assessment                                            | PBT-assessment                                                                                                 | PBT-assessment                                            |
| Parameter                                                           | Result relevant for conclusion                            |                                                                                                                | Conclusion                                                |
| Bioaccumulation                                                     | log Kow                                                   | pH 5 = 1.30 pH 7 = 3.08 pH 9 = 3.45                                                                            | not B                                                     |
| Bioaccumulation                                                     | BCF (steady- state lipid- normalised) (OECD 305)          | 336 (low concentration) and 130 (high concentration)                                                           | not B                                                     |
| Persistence                                                         | DT50 or ready biodegradabil ity                           | Sediment (two systems): - DT 50 water: 10, 9.8 d - DT 50 sediment: 353, 348 d - DT 50 whole system: 269, 338 d | vP                                                        |
| Toxicity                                                            | NOEC Daphnia sp . Reproduction Test (OECD 211)            | NOEC = 97 μg/L Toxicity to reproduction observed                                                               | T                                                         |
| PBT-statement:                                                      | The compound is not considered as PBT nor vPvB            | The compound is not considered as PBT nor vPvB                                                                 | The compound is not considered as PBT nor vPvB            |
| Phase I                                                             | Phase I                                                   | Phase I                                                                                                        | Phase I                                                   |
| Calculation                                                         | Value                                                     | Unit                                                                                                           | Conclusion                                                |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.033                                                     |  g/L                                                                                                          | > 0.01 threshold (Y)                                      |
| Other concerns (e.g. chemical class)                                |                                                           |                                                                                                                | (N)                                                       |
| Phase II Physical-chemical properties and fate                      | Phase II Physical-chemical properties and fate            | Phase II Physical-chemical properties and fate                                                                 | Phase II Physical-chemical properties and fate            |
| Study type                                                          | Test protocol                                             | Results                                                                                                        | Remarks                                                   |

<div style=\"page-break-after: always\"></div>

| Adsorption-Desorption                                            | OECD 106 or …            | Soil : K OC = 116050 L/kg (soil 1) K OC = 341959 L/kg (soil 2) K OC = 582830 L/kg (soil 3) K OC = 240301 L/kg (soil 4) Sludge: K OC = 683 L/kg (sludge 1) K OC = 1180 L/kg (sludge 2)        | Soil : K OC = 116050 L/kg (soil 1) K OC = 341959 L/kg (soil 2) K OC = 582830 L/kg (soil 3) K OC = 240301 L/kg (soil 4) Sludge: K OC = 683 L/kg (sludge 1) K OC = 1180 L/kg (sludge 2)   | Soil : K OC = 116050 L/kg (soil 1) K OC = 341959 L/kg (soil 2) K OC = 582830 L/kg (soil 3) K OC = 240301 L/kg (soil 4) Sludge: K OC = 683 L/kg (sludge 1) K OC = 1180 L/kg (sludge 2)        | Average K OC soil = 320285 L/kg                                                                                      |
|------------------------------------------------------------------|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| Ready Biodegradability Test                                      | OECD 301                 | OC                                                                                                                                                                                           | OC                                                                                                                                                                                      | OC                                                                                                                                                                                           | NA                                                                                                                   |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 308                 | System 1 at 12°C - DT 50 , water = 10 d - DT 50 , sediment = 353 d - DT 50 , whole system = 269 d - shifting to sediment = 97.6% System 2 at 12°C - DT 50 , water = 9.8 d - DT 50 , sediment | = 348 d                                                                                                                                                                                 | System 1 at 12°C - DT 50 , water = 10 d - DT 50 , sediment = 353 d - DT 50 , whole system = 269 d - shifting to sediment = 97.6% System 2 at 12°C - DT 50 , water = 9.8 d - DT 50 , sediment | Two water, sediment systems evaluated. Sediment risk assessment triggered. Very persistent in sediments              |
| Phase IIa Effect studies                                         | Phase IIa Effect studies | Phase IIa Effect studies                                                                                                                                                                     | Phase IIa Effect studies                                                                                                                                                                | Phase IIa Effect studies                                                                                                                                                                     | Phase IIa Effect studies                                                                                             |
| Study type                                                       | Test protocol            | Endpoint                                                                                                                                                                                     | value                                                                                                                                                                                   | Unit                                                                                                                                                                                         | Remarks                                                                                                              |
| Algae, Growth Inhibition Test/ Species                           | OECD 201                 | NOEC                                                                                                                                                                                         | 1700                                                                                                                                                                                    | µg/L                                                                                                                                                                                         | Raphidocelis subcapitata Growth rate Yield                                                                           |
| Daphnia sp . Reproduction Test                                   | OECD 211                 | NOEC                                                                                                                                                                                         | 97                                                                                                                                                                                      | µg/L                                                                                                                                                                                         | Daphnia magna Production of immobile offspring                                                                       |
| Fish, Early Life Stage Toxicity Test                             | OECD 210                 | NOEC                                                                                                                                                                                         | 160                                                                                                                                                                                     | µg/L                                                                                                                                                                                         | Pimephales promelas Total length, wet weight, dry weight                                                             |
| Activated Sludge, Respiration Inhibition Test                    | OECD 209                 | NOEC                                                                                                                                                                                         | >10000 00                                                                                                                                                                               | µg/L                                                                                                                                                                                         | Total respiration                                                                                                    |
| Phase IIb Studies                                                | Phase IIb Studies        | Phase IIb Studies                                                                                                                                                                            | Phase IIb Studies                                                                                                                                                                       | Phase IIb Studies                                                                                                                                                                            | Phase IIb Studies                                                                                                    |
| Bioaccumulation                                                  | OECD 305                 | BCF                                                                                                                                                                                          | 11 (low concent ration) and 9.0 (high concent ration) 98 (low concent ration)                                                                                                           | L/kg                                                                                                                                                                                         | %lipids: 50% at 126 d                                                                                                |
|                                                                  |                          | BCF KgL                                                                                                                                                                                      | and 42 (high concent ration)                                                                                                                                                            |                                                                                                                                                                                              | 50% at 61 d                                                                                                          |
| Sediment dwelling organism                                       | OECD 218                 | NOEC                                                                                                                                                                                         | 1987                                                                                                                                                                                    | mg/kg                                                                                                                                                                                        | Chironomus riparius Female and male development rate; concentration as dry weight, normalized to 10% organic carbon. |

<div style=\"page-break-after: always\"></div>

## 2.2.2. Discussion and conclusion on non-clinical aspects

No new non-clinical data, have been submitted in this application, which is considered acceptable.

An updated ERA was submitted with this extension of indication.

All initial data from Phase I and II trials, which had already been considered compliant, are used to calculate the new PEC/PNEC ratios.

Selpercatinib does not appear to present a risk for aquatic organisms in the environment and is not classified as PBT or vPvB.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

| Study ID                                   | StudyTitle and Description                                                                                                                                                                                                                                                                    | Study Objectives or Outcomes                                                                                                                                                                                                                                                                                                                      | Patient, Study Participant, or Tumour Population   | Number of Treated Participants   |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|----------------------------------|
| Registration Study                         | Registration Study                                                                                                                                                                                                                                                                            | Registration Study                                                                                                                                                                                                                                                                                                                                | Registration Study                                 | Registration Study               |
| LOXO-RET-17001 (J2G-OX-JZJA; LIBRETTO-001) | A Phase 1/2 Study of Oral LOX0-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer, and Other Tumours with RET Activation. Key design features: multicentre multicohort open label single arm, and dose escalation followed by | Phase 1 Primary objective: To determine MTD and/or RP2D. Secondary objectives: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR by IRC. Secondary objectives: To assess ORR by IA DOR, TTBR, PFS, CBR, best change in tumour size by IRC and IA CNS ORR and DOR by IRC OS safety and tolerability, and PK. | RET fusion-positive NSCLC                          | 360                              |
| LOXO-RET-17001 (J2G-OX-JZJA; LIBRETTO-001) | A Phase 1/2 Study of Oral LOX0-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer, and Other Tumours with RET Activation. Key design features: multicentre multicohort open label single arm, and dose escalation followed by | Phase 1 Primary objective: To determine MTD and/or RP2D. Secondary objectives: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR by IRC. Secondary objectives: To assess ORR by IA DOR, TTBR, PFS, CBR, best change in tumour size by IRC and IA CNS ORR and DOR by IRC OS safety and tolerability, and PK. | RET-mutant MTC                                     | 319                              |
| LOXO-RET-17001 (J2G-OX-JZJA; LIBRETTO-001) | A Phase 1/2 Study of Oral LOX0-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer, and Other Tumours with RET Activation. Key design features: multicentre multicohort open label single arm, and dose escalation followed by | Phase 1 Primary objective: To determine MTD and/or RP2D. Secondary objectives: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR by IRC. Secondary objectives: To assess ORR by IA DOR, TTBR, PFS, CBR, best change in tumour size by IRC and IA CNS ORR and DOR by IRC OS safety and tolerability, and PK. | RET fusion-positive thyroid cancer                 | 56                               |
| LOXO-RET-17001 (J2G-OX-JZJA; LIBRETTO-001) | A Phase 1/2 Study of Oral LOX0-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer, and Other Tumours with RET Activation. Key design features: multicentre multicohort open label single arm, and dose escalation followed by | Phase 1 Primary objective: To determine MTD and/or RP2D. Secondary objectives: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR by IRC. Secondary objectives: To assess ORR by IA DOR, TTBR, PFS, CBR, best change in tumour size by IRC and IA CNS ORR and DOR by IRC OS safety and tolerability, and PK. | RET fusion-positive other cancers                  | 45                               |
| LOXO-RET-17001 (J2G-OX-JZJA; LIBRETTO-001) |                                                                                                                                                                                                                                                                                               | Phase 1 Primary objective: To determine MTD and/or RP2D. Secondary objectives: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR by IRC. Secondary objectives: To assess ORR by IA DOR, TTBR, PFS, CBR, best change in tumour size by IRC and IA CNS ORR and DOR by IRC OS safety and tolerability, and PK. | Other cancers                                      | 26                               |
| LOXO-RET-17001 (J2G-OX-JZJA; LIBRETTO-001) | dose expansion.                                                                                                                                                                                                                                                                               | Phase 1 Primary objective: To determine MTD and/or RP2D. Secondary objectives: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR by IRC. Secondary objectives: To assess ORR by IA DOR, TTBR, PFS, CBR, best change in tumour size by IRC and IA CNS ORR and DOR by IRC OS safety and tolerability, and PK. | Totala                                             | 806                              |

- LIBRETTO-121,a multicentre, open-label, Phase 1/2 study in paediatric patients with an advanced solid or primary central nervous system tumour harbouring, an activating RET alteration.

## 2.3.2. Pharmacokinetics

Selpercatinib  is  an  orally  available,  highly  selective,  adenosine  triphosphate  (ATP)-competitive  small molecule inhibitor of the RET receptor tyrosine kinase.

In Europe selpercatinib is available as two strengths of hard capsules, 40 and 80 mg.

Selpercatinib is orally administered and the recommended dose is based on body weight:

- Less than 50 kg: 120 mg twice daily.
- 50 kg or greater: 160 mg twice daily.

The pharmacokinetic (PK) properties of selpercatinib were sufficiently characterized in the initial MAA (EMEA/H/C/005375/0000)

The PK data provided in support of this submission includes:

- Descriptive analysis of selpercatinib non-compartmental PK data from adult patients with RET fusion-positive  TC  (with  or  without  previous  systemic  therapy  other  than  radioactive  iodine) enrolled in the pivotal study LOXO-RET-17001 (LIBRETTO-001) as of the cut-off date (10 June 2021) and,

<div style=\"page-break-after: always\"></div>

- Summary of steady state PK parameters (Cmax and AUC0-24h) in 4 paediatric patients (aged 13 months through 10 years) treated with dose of 90 mg/m2 BID up to a maximum of 160 mg BID in the setting of single-patient compassionate use protocols.

No PK data were available from the dedicated paediatric study LIBRETTO-121.

## Pharmacokinetic in target populations

## PK data in Adult patients with thyroid cancer

PK data from study LOXO-RET-17001 as of the data cutoff of 10 June 2021 were previously reported in procedures EMEA/H/C/005375/II/0011 and EMEA/H/C/005375/II/0014. Of the 757 patients with evaluable PK data, 51had TC. Table 4 . presents the available steady-state exposure (AUC0-24 and Cmax at steady state [C1D8]) of selpercatinib for patients with TC taking 160 mg selpercatinib BID with (TC:TrtSys) or without (TC:TrtSysnaïve; Naïve patients) a previous systemic therapy.

Table 4. Steady-state (C1D8) PK parameters of selpercatinib in patients with TC taking 160 mg BID of capsule formulation

|                | TC:TrtSvsNaive   | TC:TrtSvsNaive    | TC:IrtSys    | TC:IrtSys         |
|----------------|------------------|-------------------|--------------|-------------------|
|                | Cma1 (ng/mL)     | AUC0-24 (ng*h/mL) | Cma1 (ng/mL) | AUC0-24 (ng*h/mL) |
| N              | 16               | 16                | 23           | 23                |
| Geometric mean | 2880             | 52900             | 3400         | 61000             |
| Geometric CV%  | 28               | 28                | 40           | 44                |
| 10 %56         | 1740,4260        | 32200,86900       | 1850,6300    | 31100,122000      |

Abbreviations: AUC0-24 = area under the plasma concentration-time curve from time 0 to 24 hours; BID = twice daily; CI = confidence interval; Cmax = maximum plasma concentration; CV = coefficient of variation; N =number of samples; RAI = radioactive iodine; TC = thyroid cancer; TrtSys = Patients Previously Treated with Systemic Therapy; TrtSysNaïve = Patients Not Previously Treated with Systemic Therapy other than RAI. Sources: Data available from 09 May 2017 to 10 June 2021

Figure 1. Bar charts of plasma selpercatinib Cmax and AUC0-24 following selpercatinib 160 mg BID administrations (C1D8) in patients with RET Fusion-Positive thyroid cancer

<!-- image -->

<div style=\"page-break-after: always\"></div>

## PK data in Adolescent patients with thyroid cancer

At the time of the current submission, no data in adolescent patients were present in the ongoing pivotal studyLOXO-RET-17001 LIBRETTO-001 in the advanced RET fusion-positive TC population.

As of 08 May 2022, 6 patients with RET fusion-positive TC aged 12 to 18 years have been treated in Study LIBRETTO 121 however no PK data were analysed and available: These include:

- 4 patients aged 12 years
- 1 patient aged 15 years, and
- 1 patient aged 17 years.

During the procedure PK data from 19 evaluable paediatric patients ≥ 12 years old were provided from the ongoing pivotal paediatric Study LIBRETTO-121 (data available up 13 January 2023)

Table 5. Selpercatinib Pharmocokinatics and Demographics in paediatric Patients in study LIBRETTO121 Aged 12 years and older Stratified by Actual administered dose amount at cycle 1 Day 8

|                    | Geometric Mean (%CV)                  | Geometric Mean (%CV)                | Geometric Mean (%CV)                 |
|--------------------|---------------------------------------|-------------------------------------|--------------------------------------|
| Dose               | LIBRETTO-121 Patients ≥ 12 Year's N=9 | LIBRETTO-121 Patients≥12 Year's N=5 | LIBRETTO-121 Patients ≥ 12 Years N=5 |
|                    |                                       | 92 mg/m² BID                        |                                      |
| Agea               | 16 (12-20)                            | 15 (13-19)                          | 13 (12-20)                           |
| Weighta,b          | 63.5 (56.1-97.7)                      | 51.1 (48.3-54.7)                    | 42.6 (38.6-46.1)                     |
| Cmax (ng/mL)       | 3310 (28)                             | 3580 (23)                           | 3910 (36)                            |
| AUC(0-24)(h.ng/mL) | 52900 (46)                            | 60000 (20)                          | 61800 (42)                           |

Abbreviations: AUC(0-24)=area under the plasma concentration-time curve from time 0 to 24 hours; BID = twice daily; Cmax = maximum plasma concentration; CV = coeficient of variation; N = number of patients.

a Median (minimum - maximum).

b Based on baseline value at visit Cycle 1 Day 1 (C1D1). Weights at screening were substituted for 2 patients who were missing weight measurements at CiD1.

The applicant provided PK data in 4 paediatric patients (aged 13 months through 10 years) treated in the setting of single-patient compassionate use protocols and who received the dose of 90 mg/m2 BID up to a maximum of 160 mg BID.

According to the Applicant, steady-state exposure of these paediatric patients Table 6 were well within the variability band of exposures in adults patients in LIBRETTO-001 given 160 mg BID (geometric mean Cmax of 3050 ng/mL and geometric CV% of 51.4%, geometric mean AUC0-24 of 52600 ng*h/mL, and geometric CV% 55.5%).

<div style=\"page-break-after: always\"></div>

Table 6. Pharmacokinetic Parameters of Selpercatinib in Cancer Patients Treated Through SinglePatient Compassionate Use Protocols - Paediatric

| Patient Age   | Dose        | Day 8(Steady-State)Exposure   | Day 8(Steady-State)Exposure   |
|---------------|-------------|-------------------------------|-------------------------------|
|               |             | max (ng/mL)                   | AUCo-24 (ng*h/mL)             |
| 8 years       | 80 mg BID   | 4970                          | 63300                         |
| 13 months     | 44.1 mg BID | 5280                          | 85600                         |
| 10 years      | 160 mg BID  | 3810                          | 59800                         |
| 21 months     | 42 mg BID   | 3350                          | 43200                         |

## Pharmacokinetic interaction studies

No new data have been submitted as part of this application .

## 2.3.3. Pharmacodynamics

## Mechanism of action

No new data have been submitted as part of this application.

## Primary and secondary pharmacology

No new data have been submitted as part of this application.

## 2.3.4. Discussion on clinical pharmacology

In the current submission, the applicant claims an extension of indication for selpercatinib in advanced RET fusion-positive TC to include treatment in a first-line setting and to include adolescent patients ≥12 years.

For the purpose of first-line treatment in adults, updated PK data in adult TC patients from the pivotal study LOXO-RET-17001were provided. Of the 757 patients with evaluable PK data in the ongoing pivotal study LOXO-RET-17001 (data available up to 10 June 2021), 51 patients had TC but only PK data from 39 patients were provided.

Using a Noncompartmental analysis (NCA) approach, PK exposure parameters at steady-state (AUC024h, Cmax) were determined from RET fusion-positive TC patients naïve to previous systemic therapy (n=16) and TC patients previously treated with systemic therapy (n=23). Overall , steady state systemic exposure of selpercatinib in patients with TC naïve vs those with prior systemic therapy appears to be similar. The geometric means of steady state PK parameters on selpercatinib in naïve TC patients (n=16, Cmax = 2880 ng/mL and AUC0-24h = 52900 ng.h/mL) were slightly lower (15 and 13%, respectively) than those in TC patients with prior systemic therapy (n=23, Cmax = 3400 ng/mL and AUC0-24h = 61000 ng.h/mL) and their 95% CI substantially overlapped.

The provided PK results in TC patients indicate that steady-state PK following 160 mg BID administration for patients with RET fusion-positive TC appears overall similar to those already reported for patients with NSCLC and MTC (geometric means of Cmax between 2630 and 3600 ng/mL and AUC0-24h between 45500 to 64000 ng.h/mL). Therefore from a PK perspective, the recommendation of the same dosing

<div style=\"page-break-after: always\"></div>

regimen, as reported in the current product information, for the first-line setting in patients with TC is supported.

For the purpose of extension indication in adolescent patients the PK data from 19 evaluable paediatric patients with age 12 years or older (data available up 13 January 2023) were provided from the ongoing pivotal paediatric Study LIBRETTO-121. Using the NCA approach, , the geometric means of steady-state (C1D8) selpercatinib systemic exposures in adolescents ≥12 years old receiving a 92 mg/m2 dosing (n= 19,  Cmax  =  3530  ng/mL  and  AUC0-24h  =  57000  ng.h/mL)  were  in  a  similar  range  (15  and  7%, respectively higher) compared to those observed in adult patients with cancer treated with 160 mg BID in the pivotal Study LOXO-RET-17001 (n= 646, Cmax = 3060 ng/mL and AUC0-24h = 53000 ng.h/mL) and the distributions of Cmax and AUC0-24h largely overlapped. Importantly, the 92 mg/m2 BID dosing used in pediatric patients ≥12 years old turns to nominal administered doses of 120 to 160 mg BID, which is in line with the actually recommended doses in adults.

Furthermore, when analysed by dose level, paediatric patients ≥12 years old, body weight &lt;50 kg, and administered dose of 120 mg BID (n= 5) had comparable systemic exposures at steady state (Cmax = 3910ng/mL and AUC0-24h = 61800 ng.h/mL) with paediatric patients ≥12 years old, body weight &gt;50 kg, and administered dose of 160 mg BID (n = 9, Cmax = 3310 ng/mL and AUC0-24h = 52900 ng.h/mL) as  well  adult  patients  with  160  mg  BID.  Overall,  based  on  these  results,  the  systemic  exposure  on selpercatinib at steady state in adolescent patients ≥12 years old receiving the actual recommended weight-based dosing regimen for adults [120 mg BID in patients below 50 kg and 160 mg BID in patients who are at least 50 kg] is expected to be similar to that observed in the already approved adult patients (160 mg BID).

## 2.3.5. Conclusions on clinical pharmacology

No significant difference in PK characteristics of selpercatinib is observed in naïve RET fusion-positive TC patients compared to those previously treated with systemic therapy. Therefore, from a PK perspective, the claim to extend selpercatinib indication to first-line setting in adult TC patients is agreed.

Based on interim PK from 19 evaluable paediatric patients with age 12 years or older (data available up 13 January 2023) issued from the ongoing pivotal pediatric Study LIBRETTO-121 data, the systemic exposure on selpercatinib at steady state in adolescent patients ≥12 years old administered the actual recommended  weight-based  dosing  regimen  in  adults  was  found  to  be  in  as  similar  range  to  that observed  in  adult  patients  with  cancer.  Therefore,  from  a  PK  perspective,  the  claim  to  extend selpercatinib indication to adolescents ≥12 years old is agreed.

## 2.4. Clinical efficacy

## 2.4.1. Main study(ies)

## Title of Study

## LIBRETTO-001

<div style=\"page-break-after: always\"></div>

## Methods

LIBRETTO-001 is a first in human Phase 1/2, multicentre, single-arm, multicohort, open-label, doseescalation study in patients aged 12 years or older with advanced solid tumours, including RET fusionpositive solid tumours, RET-mutant MTC, and other tumours with RET activation.

As a note, the LIBRETTO-001 study has been the basis to support the following indications:

Retsevmo as monotherapy is indicated for the treatment of adults with:

- -advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor
- -advanced RET fusion positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib

Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC).

The study includes 2 parts:

- Phase 1 (dose escalation and expansion) and
- Phase 2 (dose expansion).

After completion of the Phase 1 dose-escalation portion, the Phase 2 dose expansion to enrol patients with RET fusion-positive or RET-mutant cancers was initiated. Phase 2 cohorts were defined based on disease characteristics and patient history, for example, measurable or non-measurable disease, prior systemic therapy or systemic therapy naïve. Patients contributing to the RET fusion-positive TC population come from both Phases 1 and Phase 2 portions of the study. Assessments and by IRC (Independent Review Committee) and by Investigator were planned to be included.

Figure 2. Study design as of protocol version 9.0.

<!-- image -->

Abbreviations: cfDNA = circulating free tumour DNA; MTC = medullary thyroid cancer; MTD = maximum tolerated dose; RET = REarranged during Transfection.

<div style=\"page-break-after: always\"></div>

## Phase I dose escalation part

## Study participants

Eligibility criteria at the time of this interim report was specified as per protocol Version 9.0. (15 June 2021 data cut-off). Main selection criteria for phase 1 were: Inclusion Criteria ● Patients with a locally advanced or metastatic solid tumor who: - have progressed on or are intolerant to standard therapy, or - no standard therapy exists, or in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or - decline standard therapy. ● Prior MKIs with anti-RET activity were allowed. ● A RET gene alteration was not required initially. Once adequate PK exposure was achieved, evidence of RET gene alteration in tumor and/or blood was required (e.g., gene rearrangement and/or mutation, excluding synonymous, frameshift, or nonsense mutations) as identified through molecular assays, as performed for clinical evaluation. The RET alteration result should have been generated from a laboratory with CLIA, ISO/IEC, CAP or other similar certification. The Sponsor should have been contacted to discuss test results from labs where such certification was not clearly demonstrated to determine eligibility. ● Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate to tumor type. ● At least 18 years of age. - For countries and sites where approved, patients as young as 12 years of age could be enrolled. · Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (age ≥ 16 years) or Lansky Performance Score (LPS) ≥ 40% (age &lt; 16 years) with no sudden deterioration 2 weeks prior to the first dose of study treatment. ● Life expectancy of at least 3 months. Exclusion Criteria for Phase 1

- an additional validated oncogenic driver that could cause resistance to selpercatinib treatment.

## Outcomes/endpoints

## Phase 1 primary objective

The primary objective of the Phase 1 portion of LIBRETTO-001 was to determine the MTD and recommended Phase 2 dose of selpercatinib. A dose of 160 mg BID was selected for Phase 2.(please ref to sectino 2.3.4)

## Phase 2 dose expansion part

<div style=\"page-break-after: always\"></div>

## Inclusion Criteria for Phase 2

Inclusion Criteria are the same as for Phase 1, with the following modifications:

- Cohorts 1 and 3: failed or intolerant to standard of care; Cohorts 2 and 4: without prior standardfirst line therapy.
- Cohorts 1-4: enrollment was to be restricted to patients with evidence of a RET gene alteration in tumor (i.e., not just blood) as defined in Table 7 . However, a positive germline DNA test for a RET gene mutation as defined in Table 7 was acceptable in the absence of tumor tissue testing for patients with MTC.
- Cohorts 1-4: at least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate to tumor type and not previously irradiated (unless PD for the irradiated lesion[s] has been radiographically documented).
- Cohort 4: radiographic Progression Disease within the previous 14 months.
- Cohort 6: patients otherwise eligible for Cohorts 1-5 who discontinued another selective RET inhibitor(s) due to intolerance may be eligible with prior Sponsor approval.

Table 7. Standard of Care Therapies for Cohorts 1-4

| COHORT                                     | THERAPY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cohort 1: RET Fusion- Positive Solid Tumor | NSCLC: platinum-based chemotherapy (or other chemotherapy if not eligible for platinum) or PD-1/PD-L1 immunotherapy or both Thyroid: sorafenib and/or lenvatinib, patients must also be radioactive iodine- refractory as appropriate Colorectal: fluoropyrimidine-based chemotherapy, with or without anti- VEGF-directed therapy or anti-EGFR-directed therapy as appropriate for the disease Pancreas: fluoropyrimidine-based, gemcitabine-based, or S-1 chemotherapy Breast: anthracycline, taxane, HER2-directed therapy and/or hormonal therapy or other standard therapy appropriate for the disease Other: prior standard therapy for the disease |
| Cohort 2: RET Fusion- Positive Solid Tumor | Without prior standard-first line therapy, only if Inclusion Criteria 1 from Phase 1 is met: no standard therapy exists, or in the opinion of the Investigator is not a candidate for or would be unlikely to tolerate or derive significant clinical benefitfrom standard therapy, or decline standard therapy                                                                                                                                                                                                                                                                                                                                           |
| Cohort 3: RET-mutant MTC                   | Cabozantinib or vandetanib or both agents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Cohort 4:RET-mutant MTC                    | Without prior standard-first line therapy, only if Inclusion Criteria 1 from Phase 1 is met: no standard therapy exists, or in the opinion of the Investigator is not a candidate for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or decline standard therapy                                                                                                                                                                                                                                                                                                                                          |

## Exclusion Criteria for Phase 2

- Phase 2 Cohorts 1-4: an additional validated oncogenic driver that could cause resistance to selpercatinib treatment.

<div style=\"page-break-after: always\"></div>

## Treatments

The recommended Phase 2 dose of 160 mg twice daily (BID) was selected in Phase 1 and has been used as the starting dose for patients in the ongoing Phase 2 dose expansion.

Details of selpercatinib administration remained the same as for the authorized indication in second line of treatment of RET-fusion advance or metastatic TC.

Individual patients continued selpercatinib dosing until progressive disease, unacceptable toxicity, or other reason for treatment discontinuation.

Patients with progressive disease could continue selpercatinib if the patient was deriving clinical benefit from continuing selpercatinib, as determined by the Investigator and if continuation of selpercatinib was approved by the Sponsor.

## Objectives

Please see the outcomes and endpoints section.

## Outcomes/endpoints

The following table lists the objectives and endpoints for the Phase 2 part of the study as per protocol Version 9.0.

Table 8. Objectives and Endpoints for the Phase 2 part

| Objectives (Phase 2)                                                                                      | Endpoints (Phase 2)                                                                                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                   |                                                                                                                                                                                                                                                                  |
| To assess the anti-tumour activity of selpercatinib in patients with RET fusion-positive TC               | ORR based on IRC assessment using RECIST v1.1                                                                                                                                                                                                                    |
| Secondary                                                                                                 |                                                                                                                                                                                                                                                                  |
| To assess the anti-tumour activity of selpercatinib in patients with RET fusion-positive TC               | ORR based on Investigator assessment using RECIST v1.1 TTR, TTBR, DoR, CBR based on IRC and Investigator assessment PFS based on IRC and Investigator assessment, and OS                                                                                         |
| To determine the safety profile and tolerability of selpercatinib in patients with RET fusion-positive TC | Safety per CTCAE (including but not limited to): frequency, severity, and relatedness of TEAEs, SAEs, deaths, and clinical laboratory abnormalities changes in haematology and blood chemistry values assessments of physical examinations vital signs, and ECGs |

<div style=\"page-break-after: always\"></div>

| Objectives (Phase 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Endpoints (Phase 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To characterise the PK properties of selpercatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Plasma concentrations of selpercatinib and PK parameters, including, but not limited to, AUCo-24. Cmax, and Tmax                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Abbreviations: AUCo-24= area under the plasma concentration-time curve from O to 24 hours; CBR = clinical benefit rate; Cmx = maximum observed dnug concentration; CTCAE = Common Terminology Criteria for Adverse Events; DoR = duration of response; ECG = electrocardiogram; IRC =Independent Review Committee; ORR = overall response rate; OS = overall survival; PFS = progression-free suvival; PK = pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors; RET = REarranged during Transfection; SAE = serious adverse event; TC = thyroid cancer; TEAE = treatment-emergent adverse event; Tmax = time to maximum plasma | Abbreviations: AUCo-24= area under the plasma concentration-time curve from O to 24 hours; CBR = clinical benefit rate; Cmx = maximum observed dnug concentration; CTCAE = Common Terminology Criteria for Adverse Events; DoR = duration of response; ECG = electrocardiogram; IRC =Independent Review Committee; ORR = overall response rate; OS = overall survival; PFS = progression-free suvival; PK = pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors; RET = REarranged during Transfection; SAE = serious adverse event; TC = thyroid cancer; TEAE = treatment-emergent adverse event; Tmax = time to maximum plasma |

## Sample size

For Phase 2, For Cohort 2 a true ORR of ≥ 55% was hypothesized when selpercatinib was administered to patients with RET fusion-positive solid tumors without prior standard first-line therapy. A sample size of 59 patients was estimated to provide 85% power to achieve a lower boundary of a two-sided 95% exact binomial CI about the estimated ORR that exceeds 35%.

## Randomisation

Not applicable, this is a single-arm study.

## Blinding (masking)

Not applicable, this is an open-label study.

## Statistical methods

The efficacy analyses was to be conducted on all treated patients unless otherwise specified.

Patients with RET fusion-positive TC who had received at least 1 dose of selpercatinib and achieved at least 6 months of potential follow-up time from the first dose of selpercatinib (or disease progression or death, whichever occurred first), as of 15 June 2021, were considered eligible for efficacy analyses. Response were to be assessed approximately every 2 months. Six (6) months of follow-up provides sufficient time for initial responses to be confirmed.

ORR was to be assessed using RECIST 1.1. The estimate of the ORR was to be calculated based on the maximum likelihood estimator (i.e., crude proportion of patients with best overall response of CR or PR that are confirmed based on RECIST 1.1). The estimate of the ORR was to be accompanied by 2-sided CIs with various coverage probabilities (e.g., 80%, 95%).

The analysis of ORR was to be conducted both by the responses determined by each Investigator and responses as determined by IRC.

This interim CSR follows the SAP Version 1.0 7 August 2019.

## Measures to Minimise Bias

This study included an IRC for efficacy assessments in addition to the Investigator assessments. The primary radiography imaging files from LIBRETTO-001 were sent to a third-party vendor for central review.

## Missing data

<div style=\"page-break-after: always\"></div>

Unless noted otherwise, missing data was not to be imputed. All analyses were planned to be  based on observed data only. The effective sample sizes at each assessment visit were planned to be based on the total number of patients with non-missing data for the parameter of interest at that visit.

This interim CSR follows the SAP Version 1.0 7 August 2019 which does not specify the analysis for the subset RET Fusion-Positive TC without prior systemic treatment.

## Results

LIBRETTO-001 is currently ongoing and continues to enrol patients with advanced solid tumours.

Data presented below are from LIBRETTO-001, as of a data cutoff date of 15 June 2021 and data cutoff date of 13 January 2023, in patients with advanced or metastatic RET fusion-positive TC.

## Participant flow

At the data cutoff date, 15 June 2021 921 patients were screened. Of these, 123 patients were screen failures, and 2 patients were in screening.

Overall, 796 patients from both Phase 1 cohorts and Phase 2 dose-expansion cohorts were treated with at least 1 dose of selpercatinib as of the data cut-off date.

54 patients with RET fusion-positive TC from Phase 1 and Phase 2 Cohorts 1, 2, 5, and 6 were considered as part of the TC safety analysis dataset.

The evaluation of efficacy consists of RET fusion-positive TC analysis sets includes patients enrolled into Phase 2 Cohorts 1, 2, and 5.

The efficacy analysis for RET fusion-positive TC primarily focused on:

1. patients not previously treated with systemic therapy other than RAI nr 16 (primary efficacy analysis set) and

2. patients previously treated with systemic therapy nr 30 (supportive efficacy analysis set).

A total of 46 patients with RET fusion-positive TC were considered eligible for efficacy analyses, among them 16 patients were not previously treated with systemic therapy other than RAI (TC:TrtSysNaïve)

<div style=\"page-break-after: always\"></div>

| Set Name                     | Analysis Set                                                                                                               | Analysis Set Description                                                                                                                                                                       | Number of Patients per Analysis Set (Total TC Efficacy Evaluable Dataset N = 46)   |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Primary EffeacyAnaysisSet    | Primary EffeacyAnaysisSet                                                                                                  | Primary EffeacyAnaysisSet                                                                                                                                                                      | Primary EffeacyAnaysisSet                                                          |
| TC:TrtSysNaive               | Patients Not Previously Treated with systemic therapy (lenvatinib, sorafenib) and/or other systemic therapy other than RAI | Include patients with RET fusion- posilive TC that have had no prior systemic therapy (leuvatinib, sorafemib) and/or other systemic therapy other than RAI and met the criteria in footnote a. | N=16                                                                               |
| SecondaryEficacy.AnalysisSet | SecondaryEficacy.AnalysisSet                                                                                               | SecondaryEficacy.AnalysisSet                                                                                                                                                                   | SecondaryEficacy.AnalysisSet                                                       |
| TC:TrtSys                    | Patients Previously Treated with systemic therapy (lenvatinib, sorafenib) and/or other systemic therapy                    | Includes all patients with RET fusion-positive TC previously treated with systemic therapy (lenvatinib, sorafemib), or other systemic therapy and met the criteria in footnote a.              | N=30                                                                               |

Table 9. Description of Efficacy Analysis Sets (DCO 15 June 2021)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 3. RET Fusion-Positive TC efficacy analysis and overall safety populations based on a data cutoff date of 15 June 2021.

<!-- image -->

Abbreviations: BID = twice daily; MTC = medullary thyroid cancer: N = number of patients; NSCLC = non-small-cell lung cancer; QD = once daily; RAI = radioactive iodine; RET = REarranged during Transfectionr; TC = thyroid cancer; IC:IrtSys = Patients Previously Treated with Systemic Therapy; IC:IrtSysNaive = Patients Not Previously Treated with Systemic Therapy other than RAI.

## Recruitment

This study was conducted at 80 centres that enrolled a total of 796 patients in North America, Asia Pacific, the European Union, and the Middle East.

The study initiation date (first participant first visit) is 09 May 2017.

The data cutoff date for interim analysis is 15 June 2021.

LIBRETTO-001 is currently ongoing and continues to enrol patients with advanced solid tumours.

No patients with RET fusion-positive TC aged 18 years or less were identified for participation in LIBRETTO-001.

## Conduct of the study

Major protocol deviations for the TC Safety Population and Overall Safety Population are presented below.

<div style=\"page-break-after: always\"></div>

Figure 4. Summary of Major Protocol Deviations TC Safety Population and Overall Safety Population (DCO 15 June 2021

| Category                              | TCSafetyPopulation N=54 n (%)   | OverallSafetyPopulation N=796 n (%)   |
|---------------------------------------|---------------------------------|---------------------------------------|
| Patientswithmajorprotocol deviations  | 5 (9.3)                         | 161 (20.2)                            |
| Investigationalproduct                | 2 (3.7)                         | 61 (7.7)                              |
| Study procedure                       | 0 (0.0)                         | 43 (5.4)                              |
| SAEreporting                          | 0 (0.0)                         | 35 (4.4)                              |
| Restrictedconcomitantmedicationchange | 2 (3.7)                         | 23 (2.9)                              |
| Inclusion criteria                    | 0 (0.0)                         | 16 (2.0)                              |
| Withdrawal criteria                   | 1 (1.9)                         | 11 (1.4)                              |
| Exclusion criteria                    | 0 (0.0)                         | 5 (0.6)                               |
| Informed consent                      | 0 (0.0)                         | 4 (0.5)                               |

Abbreviations:N=number ofpatients;n=number ofpatients in the specific category;SAE=serious adverse event; TC = thyroid cancer.

## Baseline data

## Demographics

The following table presents the patients demographics by different efficacy analysis sets within the RET fusion-positive TC efficacy analysis population.

No patients with RET fusion-positive TC aged 18 years or less were identified for participation in LIBRETTO-001.

Table 10: Baseline Characteristics of patients with RET Fusion-Positive TC in LIBRETTO-001 (DCO 13 Jan 2023)

| Characteristics           | Treated (N= 41)   | Naive (N= 24)   | Total Thyroid (N= 65)   |
|---------------------------|-------------------|-----------------|-------------------------|
| Sex (n, &)                |                   |                 |                         |
| Male                      | 18  (43.9)        | 14(58.3)        | 32(49.2)                |
| Female                    | 23 (56.1)         | 10 (41.7)       | 33( 50.8)               |
| Race (n, &)               |                   |                 |                         |
| White                     | 24 1(58.5)        | 18 (75.0)       | 42 (64.6)               |
| Black or African American | 3 7.3)            | 0 0.0)          | 3 4.6)                  |
| Asian                     | 12 ( 29.3)        | 1 4.2)          | 13 (20.0)               |
| Other                     | 2 4.9)            | 12.5)           | 5 7.7)                  |
| Missing                   | 0 0.0)            | 2 8.3)          | 2 3.1)                  |
| Ethnicity (n,&)           |                   |                 |                         |
| Hispanic or Latino        | 2 4.9)            | 5 (20.8)        | (10.8)                  |
| Not Hispanic or Latino    | 37 (90.2)         | 14(58.3)        | 51 (78.5)               |
| Missing                   | 2 4.9)            | 5 (20.8)        | 7 (10.8)                |
| Age Group (n,&)           |                   |                 |                         |
| 18 to<45 years            | 9(22.0)           | 5(20.8)         | 14 ( 21.5)              |
| 45to<65year9              | 15 5(36.6)        | 8( 33.3)        | 23 ( 35.4)              |
| 65 to<75years             | 7(17.1)           | 9(37.5)         | 16 (24.6)               |
| 75 to<85years             | 9(22.0)           | 2(8.3)          | 11 (16.9)               |
| 85+ years                 | 1 (2.4)           | 。（ 0.0)         | 1(1.5)                  |
| Age (years)               |                   |                 |                         |
| N                         | 41                | 24              | 65                      |
| Mean                      | 59.1              | 57.1            | 58.4                    |
| Standard Deviation        | 16.71             | 16.47           | 16.52                   |
| Median                    | 58.0              | 60.5            | 59.0                    |
| Minimum                   | 25                | 20              | 20                      |
| Maximum                   | 88                | 84              | 88                      |
| Height (cm)               |                   |                 |                         |
| N                         | 40                | 23              | 63                      |
| Mean                      | 166.9             | 168.4           | 167.4                   |
| Standard Deviation        | 12.05             | 9.91            | 11.26                   |
| Median                    | 167.0             | 171.0           | 169.0                   |
| Minimum                   | 140               | 148             | 140                     |
| Maximum                   | 197               | 186             | 197                     |

<div style=\"page-break-after: always\"></div>

| Weight (kg) N                 | 41         | 24        | 65         |
|-------------------------------|------------|-----------|------------|
| Mean                          | 70.278     | 79.625    | 73.729     |
| Standard Deviation            | 21.1714    | 21.1364   | 21.4792    |
| Median                        | 67.000     | 79.100    | 69.900     |
| Minimum                       | 40.00      | 38.90     | 38.90      |
| Maximum                       | 121.40     | 119.70    | 121.40     |
| Body MassIndex(kg/m²)         |            |           |            |
| N                             | 40         | 23        | 63         |
| Mean                          | 24.74      | 27.46     | 25.73      |
| Standard Deviation            | 5.305      | 7.047     | 6.089      |
| Median                        | 23.42      | 27.21     | 25.28      |
| Minimum                       | 15.4       | 17.8      | 15.4       |
| Maximum                       | 35.6       | 51.8      | 51.8       |
| EcoG Performance Status (n,&) |            |           |            |
| 0                             | 11 ( 26.8) | 14 (58.3) | 25 ( 38.5) |
| 1                             | 27 (65.9)  | 9(37.5)   | 36 ( 55.4) |
| 2                             | 7.3)       | 1( 4.2)   | 4（ 6.2)    |
| Smoking History(n，&)          |            |           |            |
| Never Smoked                  | 28(68.3)   | 12 (50.0) | 40(61.5)   |
| Former Smoker                 | 13 ( 31.7) | 10 (41.7) | 23 ( 35.4) |
| Current Smoker                | 。（ 0.0)    | 4.2)      | 1(1.5)     |
| Missing                       | 0.0)       | 4.2)      | 1( 1.5)    |
| Phase2Cohort(n，&)             |            |           |            |
| Cohort 1                      | 32 (78.0)  | ○（ 0.0)   | 32 (49.2)  |
| Cohort 2                      | 5 (12.2)   | 18 (75.0) | 23 (35.4)  |
| Cohort 5                      | 9.8)       | 6 (25.0)  | 10 (15.4)  |

Percentage is calculated using the number of patients in the column heading as the denominator.

Baseline is defined as the last measurement available prior to the first dose of Loxo-292.

Eligible patients are defined as treated patients. Phase 2 patients enrolled in cohort 'coHoRT 6 ELIGIBLE FOR CoHoRTS 1-5 BUT DISCONTINUED SELECTIVE RET INHIBITOR(S) DUE TO INTOLERANCE'aYe eXCluded.

## Baseline Disease Characteristics

The following table presents the baseline disease characteristics by different analysis sets within the RET fusion-positive TC efficacy analysis population.

Table 11 Cancer History (RET Fusion-Positive TC) Efficacy Population DCO 13 Jan 2023)

| Characteristics                      | Treated (N= 41)   | Naive (N= 24)   | Total Thyroid (N= 65)   |
|--------------------------------------|-------------------|-----------------|-------------------------|
| Primary Diagnosis (n, )              |                   |                 |                         |
| Thyroid                              | 41(100.0)         | 24(100.0)       | 65 (100.0)              |
| Papillary Thyroid Cancer             | 31 ( 75.6)        | 23 ( 95.8)      | 54 ( 83.1)              |
| Poorly Differentiated Thyroid Cancer | 5( 12.2)          | 1(4.2)          | 6(9.2)                  |
| Anaplastic Thyroid Cancer            | 4(9.8)            | 0（ 0.0)         | 4( 6.2)                 |
| Hurthle Cell Thyroid Cancer          | 1（ 2.4)           | 0.0)            | 1( 1.5)                 |
| Stage at Entry （n,)                  |                   |                 |                         |
| II                                   | 1 (2.4)           | 0（ 0.0)         | 1( 1.5)                 |
| III                                  | 2(4.9)            | 0 0.0)          | 2 (3.1)                 |
| IV                                   | 20(48.8)          | 16 ( 66.7)      | 36 ( 55.4)              |
| IVA                                  | 0(0.0)            | 1( 4.2)         | 1 (1.5)                 |
| IVB                                  | 4(9.8)            | 4(16.7)         | 8(12.3)                 |
| IVC                                  | 12 (29.3)         | 3(12.5)         | 15 ( 23.1)              |
| Missing                              | 2 (4.9)           | 0(0.0)          | 2(3.1)                  |
| Months since Initial Diagnosis       |                   |                 |                         |
| N                                    | 41                | 24              | 65                      |
| Mean                                 | 148.44            | 124.34          | 139.54                  |
| Standard Deviation                   | 137.603           | 154.612         | 143.396                 |
| Median                               | 102.10            | 65.85           | 94.10                   |
| Minimm                               | 2.6               | 2.1             | 2.1                     |
| Maximm                               | 562.7             | 574.9           | 574.9                   |
| History of Metastatic Disease (n, )  | 41(100.0)         | 24 (100.0)      | 65 (100.0)              |
| Months since Metastatic Disease      |                   |                 |                         |
| N                                    | 41                | 24              | 65                      |
| Me an                                | 88.18             | 69.14           | 81.15                   |
| Standard Deviation                   | 110.456           | 84.830          | 101.475                 |
| Median                               | 43.70             | 25.90           | 42.10                   |
| Minimm                               | 1.9               | 1.1             | 1.1                     |
| Maximum                              | 494.9             | 298.9           | 494.9                   |

## Prior Cancer Therapy

Of the 16 TC:TrtSysNaïve patients, 93.8% received prior RAI and no patients received other systemic therapy, including MKI therapy or chemotherapy.

<div style=\"page-break-after: always\"></div>

The median number of prior rounds of RAI, was 1 (range, 0 to 4).

Table 12. Prior Cancer Therapy RET Fusion-Positive TC Efficacy Analysis Population Population (Data Cutoff: 13 January 2023)

| Characteristics                                | Treated [5] (N= 41)   | Naive [5] (N= 24)   | Total Thyroid (N= 65)   |
|------------------------------------------------|-----------------------|---------------------|-------------------------|
| Received Prior Systemic Therapy (n, &)         |                       |                     |                         |
| Yes                                            | 41 (100.0)            | 18 (75.0)           | 59(90.8)                |
| No                                             | 0(0.0)                | 6(25.0)             | 6(9.2)                  |
| Type of Prior Systemic Therapy [1] (n,&)       |                       |                     |                         |
| MKI                                            | 35 ( 85.4)            | 0 0.0)              | 35 (53.8)               |
| Cabozantinib                                   | 1 (2.4)               | 0 0.0)              | 1 1.5)                  |
| Vandetanib                                     | 1 (2.4)               | 0 0.0)              | 1 1.5)                  |
| Sorafenib                                      | 9(22.0)               | 0 0.0)              | (13.8)                  |
| Lenvatinib                                     | 26 ( 63.4)            | 0 0.0)              | 26 （40.0)               |
| Both Sorafenib and Lenvatinib                  | (9.8)                 | 0 0.0)              | 4 6.2)                  |
| Other MKIs [2]                                 | (17.1)                | 0 0.0)              | 7 (10.8)                |
| Chemotherapy                                   | 8(19.5)               | 0 0.0)              | (12.3)                  |
| Platinum Chemotherapy                          | 4 （ 9.8)              | 0 0.0)              | 4 6.2)                  |
| Taxane Chemotherapy                            | 5 (12.2)              | 0 0.0)              | 5 7.7)                  |
| Number of Prior Systemic Regimens (n, &)       |                       |                     |                         |
| 0                                              | 0(0.0)                | 6(25.0)             | 6(9.2)                  |
| 1                                              | 10(24.4)              | 10(41.7)            | 20 (30.8)               |
| 2                                              | 8 (19.5)              | 3(12.5)             | 11 (16.9)               |
| 3 or more                                      | 23 (56.1)             | 5(20.8)             | 28 (43.1)               |
| Number of Prior Systemic Regimens              |                       |                     |                         |
| N                                              | 41                    | 24                  | 65                      |
| Mean                                           | 3.1                   | 1.5                 | 2.5                     |
| Standard Deviation                             | 1.86                  | 1.41                | 1.87                    |
| Median                                         | 3.0                   | 1.0                 | 2.0                     |
| Minimum                                        | 1                     | 0                   | 0                       |
| Maximum                                        | 7                     | 5                   | 7                       |
| Type of Prior Systemic Therapy [1] (n,&)       |                       |                     |                         |
| Immunotherapy                                  | 3 7.3)                | 0 0.0)              | 3 4.6)                  |
| Anti-PD1/PD-L1 Therapy                         | 3 7.3)                | 0 0.0)              | 3 4.6)                  |
| Anti CTLA4 Therapy                             | 0 0.0)                | 0 0.0)              | 0 0.01                  |
| Other                                          | 30 （ 73.2)            | 18 75.0)            | 48 73.81                |
| Radioactive Iodine                             | 30 73.2)              | 18 75.0)            | 48 73.8)                |
| mTOR Inhibitor                                 | 2 4.9)                | 0 0.0)              | 2 3.1)                  |
| EGRF Inhibitor                                 | 1 2.4)                | 0 0.0)              | 1 1.5)                  |
| VEGF/VEGFR Inhibitor                           | 0 0.0)                | 0 0.0)              | 0 0.0)                  |
| Hormonal Therapy                               | 0 0.0)                | 0 0.0)              | 0 0.0)                  |
| Selective RET Inhibitor                        | 0 0.0)                | 0 0.0)              | 0 0.0)                  |
| Other Systemic Therapy [3]                     | 4 9.8)                | 0 0.0)              | 4 6.2)                  |
| Best Response to Last Systemic Treatment (n,&) |                       |                     |                         |
| Complete Response                              | 0(0.0)                | 1 4.2)              | 1(1.5)                  |
| Partial Response                               | 8 (19.5)              | 0 0.0)              | 8(12.3)                 |
| Stable Disease                                 | 16 ( 39.0)            | 3 (12.5)            | 19 ( 29.2)              |
| Progressive Disease                            | 9(22.0)               | 2( 8.3)             | 11 (16.9)               |
| Not Evaluated Unknown [4]                      | 7(17.1) 1(2.4)        | 12 (50.0) 6( 25.0)  | 19 (29.2) 7(10.8)       |
| Prior Radiotherapy (n, &)                      |                       |                     |                         |
| Yes                                            | 20(48.8)              | 10(41.7)            | 30 (46.2)               |
| No                                             | 21 ( 51.2)            | 14 (58.3)           | 35 (53.8)               |
| Prior Cancer-Related Surgery (n,&)             |                       |                     |                         |
| Yes                                            | 34 ( 82.9)            | 23 (95.8)           | 57 ( 87.7)              |
| No                                             | 7(17.1)               | 1 (4.2)             | 8( 12.3)                |

Percentage is calculated based on the number of patients in the column heading as the denominator. Eligible patients are defined as treated patients.Phase 2 patients enrolled in cohort 'coHORT 6 ELIGIBLE FOR CoHoRTS 1-5 BUT Stable Disease includes Non-CR/Non-PD.

*Indicates SD lasting &gt;= 16 weeks following initiation of Loxo-292 until the criteria for disease progression was first met.

[2] objective Response Rate (&amp;) is defined as the proportion of patients with best overall response of confirmed CR, or PR.Response was confirmed by a repeat assessment no less than 28 days.

[1] Based on IRC assessments using RECIST (version 1.1).

[3] Clinical Benefit Rate (&amp;) is defined as the proportion of patients with best overall response of confirmed CR, PR, or stable disease lasting 16 or more weeks (SD*).Stable disease was measured from the date of the first dose Loxo-292 until the criteria for disease progression was first met.

[5]95&amp; confidence interval was calculated using Clopper-Pearson method.

[4]Disease Control Rate (&amp;) is defined as the proportion of patients with best overall response of confirmed CR, PR,or stable disease (SD).

## Numbers analysed

As of 15 June 2021, of the 46 efficacy-eligible patients with RET fusion-positive TC, 31 (67.4%) were still on treatment.

Of the 16 TC:TrtSysNaïve patients, 81.3% were still on treatment. The main reason for treatment discontinuation was:

<div style=\"page-break-after: always\"></div>

- progressive disease (1 [6.3%]),
- withdrawal of consent (1 [6.3%]), or
- other (1 [6.3%]): withdrawal of consent for greater convenience.

Table 13. Summary of Disposition RET Fusion-Positive TC Efficacy Analysis Population (Data Cutoff: 15 June 2021)

|                                                     | PrimaryAnalysisSet   | Supportive Analysis Set   | Total TC   |
|-----------------------------------------------------|----------------------|---------------------------|------------|
| n (%)                                               | TC:TrtSysNaive N=16  | TC:IrtSys N=30            | N =46      |
| Treatment continuing                                | 13 (81.3)            | 18 (60.0)                 | 31 (67.4)  |
| Treatment discontinued                              | 3 (18.8)             | 12 (40.0)                 | 15 (32.6)  |
| Progressive disease                                 | 1 (6.3)              | 6 (20.0)                  | 7 (15.2)   |
| Adverse event                                       | 0 (0.0)              | 1 (3.3)                   | 1 (2.2)    |
| Requirement for altemative treatmentperinvestigator | 0 (0.0)              | 1 (3.3)                   | 1 (2.2)    |
| Significant non-compliance to protocol              | 0 (0.0)              | 2 (6.7)                   | 2 (4.3)    |
| Withdrawal of consent                               | 1 (6.3)              | 2 (6.7)                   | 3 (6.5)    |
| Other                                               | 1 (6.3)              | 0 (0.0)                   | 1 (2.2)    |
| Treatment post-progression                          | 2 (12.5)             | 11 (36.7)                 | 13 (28.3)  |
| Study status continuing                             | 14 (87.5)            | 20 (66.7)                 | 34 (73.9)  |
| Studystatusdiscontinued                             | 2 (12.5)             | 10 (33.3)                 | 12 (26.1)  |
| Withdrawal of consent                               | 1 (6.3)              | 2 (6.7)                   | 3 (6.5)    |
| Death                                               | 1 (6.3)              | 7 (23.3)                  | 8 (17.4)   |
| Other                                               | 0 (0.0)              | 1 (3.3)                   | 1 (2.2)    |

Abbreviations: N = number of patients; n = number of patients in the specific category; RAI = radioactive iodine; RET = REarranged during Transfection; TC = thyroid cancer; IC:IrtSys = Patients Previously Treated with Systemic Therapy; TC:IrtSysNaive = Patients Not Previously Treated with Systemic Therapy other than RAI.

The data of eight more TC:TrtSysNaïve patients were added to the number analized during the assessment with a DCO of 13 January 2023.

## Outcomes and estimation

Outcomes data from Study LIBRETTO-001 submitted at the start of the current procedure (Data cutoff date of 21 June 2021) are presented below along with efficacy data cutoff of 13 January 2023.

For the set of data with DCO 13 Jan 2023 a total of 66 patients with RET fusion-positive TC were treated with at least 1 dose of selpercatinib. Of the Thyroid Cancer Efficacy Population, 24 were TC:TrtSysNaïve patients.

## Primary endpoint

Objective Response Rate, DCO 21 June 2021

<div style=\"page-break-after: always\"></div>

Table 14. Response Results RET Fusion-Positive TC Primary Efficacy Analysis Set (DCO 15 June 2021)

|                                                                                | TC:TrtSysNaive N=16   | TC:TrtSysNaive N=16     |
|--------------------------------------------------------------------------------|-----------------------|-------------------------|
|                                                                                | IRC Assessment        | Investigator Assessment |
| Objective response ratea                                                       |                       |                         |
| n(%6)                                                                          | 15 (93.8)             | 13 (81.3)               |
| 9596 CIb                                                                       | 69.8, 99.8            | 54.4, 96.0              |
| Best overallresponse, n (90)                                                   |                       |                         |
| CR                                                                             | 5 (31.3)              | 4 (25.0)                |
| PR.                                                                            | 10 (62.5)             | 9 (56.3)                |
| SD                                                                             | 1 (6.3)               | 3 (18.8)                |
| SD16+*                                                                         | 1 (6.3)               | 3 (18.8)                |
| PD                                                                             | 0 (0.0)               | 0 (0.0)                 |
| Not evaluable                                                                  | 0 (0.0)               | 0 (0.0)                 |
| Climical benefit rate (CR+PR+ SD16+)                                           |                       |                         |
| n(%)                                                                           | 16 (100.0)            | 16 (100.0)              |
| 95% CIb                                                                        | 79.4, 100.0           | 79.4, 100.0             |
| Disease control rate(CR + PR + SD)                                             |                       |                         |
| n(%6)                                                                          | 16 (100.0)            | 16 (100.0)              |
| 959% CIb                                                                       | 79.4, 100.0           | 79.4,100.0              |
| Duration of response                                                           |                       |                         |
| Responders,                                                                    | 15                    | 13                      |
| Median in months (95% C1)de                                                    | NE (19.4, NE)         | 29.7 (13.1, NE)         |
| Censored, n (%6)                                                               | 13 (86.7)             | 10 (76.9)               |
| Reason censored, n (%6)                                                        |                       |                         |
| Alive without documented disease progression                                   | 10 (66.7)             | 8 (61.5)                |
| Subsequent anti-cancer therapy or cancer-related surgery without documented PD | 2 (13.3)              | 2 (15.4)                |
| Died or documented PD after missing 2 or more consecutive visits               | 1 (6.7)               | 0 (0.0)                 |
| Rate ((o) of duration of responsed!                                            |                       |                         |
| 12 months (95%% C1)                                                            | 100.0 (NE, NE)        | 90.9 (50.8, 98.7)       |
| 24 months (95%% C1)                                                            | 77.9 (35.4, 94.2)     | 81.8 (44.7, 95.1)       |
| 36 months (95% C1)                                                             | NE (NE, NE)           | NE (NE, NE)             |
| Duration of follow-up (months)\"&                                               |                       |                         |
| Median                                                                         | 20.1                  | 20.2                    |
| 95% CI for median                                                              | 9.3, 25.8             | 15.2, 25.8              |
| 25th, 75th percentiles                                                         | 12.1,25.8             | 15.7, 25.8              |

Abbreviations: CI = confidence interval; CR = complete response; IRC = Independent Review Committee; N = mumber of patients in the population; n = number of patients per category; NE = not estimable; ORR = objective response rate; PD = progressive disease; PR =partial response; RAI = radioactive iodine; RET = REarranged duing Transfection; SD = stable disease; SD16+ = stable disease lasting 16 or more weeks; TC:TrtSysNaive = Patients Not Previously Treated with Systemic Therapy other than RAI.

- ORR is defined as the proportion of patients with best overall response of confirmed CR or PR. Response Was confirmed by a repeat assessment ≥28 days.
- b 95% CI was calculated using the Clopper-Pearson method.
- SD16+ indicates SD lasting ≥16 weeks following initiation of selpercatinib.
- d Estimate based on the Kaplan-Meier method.
- 95% CI was calculated using the Brookmeyer and Crowley method.
- f 95% CI was calculated using the Greenwood's formula.
- 名 Estimated based on the Reverse Kaplan-Meier method.
- h Disease Control Rate (%6) is defined as the proportion of patients with best overall response of confirmed CR, PR, or SD.

Note: Censored patients are represented as a percentage of responders by IRC assessment (N = 15) and Investigator assessment (N = 13).

Data cutoff date: 15 Jume 2021.

<div style=\"page-break-after: always\"></div>

Table 15. Response Results by IRC Assessment (RET Fusion-Positive TC) Efficacy Analysis Set TC:TrtSys and TC:TrtSysNaïve (DCO 13 Jan 2023)

| Data Cutoff Date                                | 13 January 2023 (N=41)   | 13 January 2023 (N=24)   |
|-------------------------------------------------|--------------------------|--------------------------|
|                                                 | TC:TrtSys                | TC:TrtSysNaive           |
| Overall response ratea,b                        |                          |                          |
| n (%)                                           | 35 (85.4)                | 23 (95.8)                |
| 95% CI                                          | (70.8, 94.4)             | (78.9, 99.9)             |
| Best overallresponse, n (%)                     |                          |                          |
| CR                                              | 5 (12.2)                 | 5 (20.8)                 |
| PR                                              | 30 (73.2)                | 18 (75.0)                |
| SDc                                             | 6 (14.6)                 | 1 (4.2)                  |
| Progressive disease                             | 0                        | 0 (0.0)                  |
| Not evaluable                                   | 0                        | 0 (0.0)                  |
| Clinical benefit rate (CR + PR + SD-16 weeksc)d |                          |                          |
| n (%)                                           | 41 (100.00)              | 24 (100.0)               |
| 95% CIb                                         | (91.4, 100.0)            | (85.8, 100.0)            |
| Time to response                                |                          |                          |
| Median in months                                | 1.81                     | 1.87                     |
| Duration of responsee,f                         |                          |                          |
| Responders, n                                   | 35                       | 23                       |
| Censored, n (%)                                 | 20 (57.1)                | 21 (91.3)                |
| Median in months (95% CI)                       | 26.71 (12.1, NE)         | NE (42.8, NE)            |
| Rate (%o) of duration of responsee;g            |                          |                          |
| ≥6 months (95% CI)                              | 91.2 (75.2, 97.1)        | 100.0 (NE, NE)           |
| ≥12 months (95% CI)                             | 71.7 (52.4, 84.2)        | 100.0 (NE, NE)           |
| Obser'veddurationofresponse                     |                          |                          |
| <6 months                                       | 5 (14.3)                 | 2 (8.7)                  |
| >=6 to 12 months                                | 11 (31.4)                | 6 (26.1)                 |
| >=12 to 18months                                | 6 (17.1)                 | 4 (17.4)                 |
| >=18 to 24 months                               | 2 (5.7)                  | 1 (4.3)                  |
| >=24 months                                     | 11 (31.4)                | 10 (43.5)                |
| Duration of follow-up (months)f, i              |                          |                          |
| Median                                          | 33.87                    | 17.81                    |

Abbreviations: CI = confidence interval; CR = complete response; IRC = independent review committee; n= number of patients per category; N = number of patients in population; NE = not estimable; ORR = objective response rate; PR = partial response; RET =REarranged during Transfection; SD = stable disease; TC = thyroid cancer.

- ORR is defined as the proportion of patients with best overall response of confirmed CR or PR. Response was confirmed by a repeat assessment of at least 28 days.
- 95% CI was calculated using Clopper-Pearson method.
- SD indicates SD lasting at least 16 weeks following initiation of selpercatinib.
- Clinical benefit rate (%) is defined as the proportion of patients with best overall response of confirmed CR, PR or SDlasting 16 or more weeks (SD-16 weeks). SD was measured from the date of the first dose of selpercatinib until the criteria for disease progression or death was first met.
- Estimate based on Kaplan-Meier method. + = censored observation.
- 95% CI was calculated using Brookmeyer and Crowley method.

## Secondary endpoints

## Progression-Free Survival DCO 21 June 2021

Table 16. Progression-Free Survival Based on IRC and Investigator Assessment RET Fusion-Positive TC Primary Efficacy Analysis Set

<div style=\"page-break-after: always\"></div>

| Status                                                                                       | TC:TrtSvsNaive N=16   | TC:TrtSvsNaive N=16     |
|----------------------------------------------------------------------------------------------|-----------------------|-------------------------|
|                                                                                              | IRC Assessment        | Iuvestigator Assessment |
| Progression status, n (96)                                                                   |                       |                         |
| Disease progression                                                                          | 3 (18.8)              | 3 (18.8)                |
| Died (no disease progression beforehand)                                                     | 0 (0.0)               | 0 (0.0)                 |
| Censored                                                                                     | 13 (81.3)             | 13 (81.3)               |
| Reason censored, n (96)                                                                      |                       |                         |
| Alivewithout documented disease progression                                                  | 10 (62.5)             | 11 (68.8)               |
| Subsequent anti-cancer therapy or cancer-related swrgery without documentprogressive disease | 2 (12.5)              | 2 (12.5)                |
| Died or docuwmentedprogressive disease after missing 2 or more consecutive visits            | 1 (6.3)               | 0 (0.0)                 |
| Progression-free survival (months)ab                                                         |                       |                         |
| Median                                                                                       | NE                    | NE                      |
| 9596 CI for median                                                                           | 19.3, NE              | 31.0, NE                |
| Min-max                                                                                      | 3.7+ - 33.0+          | 3.7+ -33.1+             |
| Duration of follow-up (months)be                                                             |                       |                         |
| Median                                                                                       | 22.1                  | 23.9                    |
| 95% CI for median                                                                            | 17.0, 27.6            | 17.0, 27.9              |
| 25h,75hpercentiles                                                                           | 17.0-27.6             | 17.0-27.9               |
| Rate (9o) of progression-free surviralu                                                      |                       |                         |
| 12 months (95% C1)                                                                           | 92.9 (59.1, 99.0)     | 92.9 (59.1, 99.0)       |
| 24 months (95% CI)                                                                           | 83.6 (48.0,95.7)      | 84.4 (50.4, 95.9)       |

Abbreviations: CI = confidence iuterval; IR.C = Independent Review Committee; N = number of patients; n = mumber of patients in the specific category: NE = not estimable; max = maximum; min = minimum; RAI = radioactive iodine; RET = REamanged during Transfection; TC = thyroid cancer; TC:IrtSysNaire = Patients Not Previously Treated with Systemic Therapy other than RAI.

- Estimute based on the Kaplan-Meier method. + = censored observation.
- h 95% CI was calculated using the Brookmeyer and Crowley method.
- G Estimate based on the Reverse Kaplan-Meier method.

Figure 5. Kaplan-Meier plot for progression-free survival based on IRC assessments RET FusionPositive TC Efficacy Analysis Set.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations: +=censored observation: IRC =Independent Review Committee; No. =muwmber: PFS =progression-fee swvival; RET =REarranged duringTransfection; TC = thyroid cancer.

## Progression-Free Survival DCO 13 Jan 2023

Table 17. Progression-Free Survival (RET Fusion-Positive TC) TC:TrtSys and TC:TrtSysNaïve DCO 13 Jan 2023

| Data CutoffDate                                | 13January2023   | 13January2023   |
|------------------------------------------------|-----------------|-----------------|
| Population                                     | TC:TrtSys       | TC:TrtSysNaive  |
| N                                              | 41              | 24              |
| Duration of progression-free survival (months) |                 |                 |
| Mediana                                        | 27.4            | NE              |
| 95%CIc                                         | 14.5, NE        | 44.2, NE        |
| Minimum, maximum                               | 3.5, 60.5+      | 3.7+, 52.4+     |
| Rate (%) of PFS                                |                 |                 |
| ≥12 monthsa                                    | 70.6            | 95.2            |
| 95% CIc                                        | (53.2, 82.6)    | (70.7,99.3)     |
| Duration ofPFSfollow-up(months)                |                 |                 |
| Medianb                                        | 30.39           | 24.94           |
| 25, 75 percentiles                             | 16.5,41.1       | 11.2, 44.0      |

Abbreviations: CI = confidence interval; CR = complete response; n = number of patients per category; N = number of patients in population; NE = not estimable; ORR = objective response rate; PFS = progression-free survival; PR = partial response; RET = REarranged during Transfection; SD = stable disease; TC = thyroid cancer.

- Estimate based on Kaplan-Meier method. NE = Not estimable. + = Censored observation.

b Estimate based on Reverse Kaplan-Meier method.

c 95% CI was calculated using Greenwood's formula.

## Overall Survival

Median OS was NE with a median follow-up time of 22.8 months (95% CI: 19.8, 29.4). The rate of OS at 12 months was 100.0% (95% CI: NE, NE) and at 24 months was 92.3% (95% CI: 56.6, 98.9).

<div style=\"page-break-after: always\"></div>

Table 18. Overall Survival RET Fusion-Positive TC Primary Efficacy Analysis Set DCO 21 June 2021

|                                  | TC:IrtSysNaire N=16   |
|----------------------------------|-----------------------|
| Survival status, n (96)          |                       |
| Died                             | 1(6.3)                |
| Censored                         | 15 (93.8)             |
| Overall survival (months)*h      |                       |
| Median                           | NE                    |
| 95% CI for median                | NE, NE                |
| Min-max                          | 10.2+-35.6+           |
| Duration of follor-up (months)be |                       |
| Median                           | 22.8                  |
| 95% CI for median                | 19.8,29.4             |
| 25h,75h percentiles              | 19.8,29.4             |
| Rate (9o) of overall survival\"d  |                       |
| 12 months (9596 C1)              | 100.0 (NE, NE)        |
| 24 months (9596 CI)              | 92.3 (56.6, 98.9)     |

Abbreviations: CI =confidence interval; max = maximim; min = minimum; N = number of patienis; n = number of patients in the specified category; NE = not estimable; RAI = radioactive iodine; RET = REarranged during Transfection; TC:TrtSysNaive = Patients Not Previously Treated with Systemic Therapy other than RAI.

- Estimate based on the Kaplan-Meier method. + = censored observation
- b 95% CI was calculated using the Brookmeyer and Crowley method.
- Estimute based on the Reverse Kaplan-Meier method.
- d 95%6 CI was calculated using the Greenwood's formula.
- Estimate based on Kaplan-Meier method.

Note: Stahus as of the last contact on or before 15 June 2021.

Data cutoff date: 15 Jume 2021.

Table 19. Overall Survival (RET Fusion-Positive TC) TC:TrtSys and TC:TrtSysNaïve DCO 13 Jan 2023

| Data Cutoff Date                  | 13 January 2023   | 13 January 2023   |
|-----------------------------------|-------------------|-------------------|
| Population                        | TC:TrtSys         | TC:TrtSysNaive    |
| N                                 | 41                | 24                |
| Duration of OS (months)           |                   |                   |
| Mediana                           | NE                | NE                |
| 95% CIb                           | 25.3, NE          | NE, NE            |
| Minimum,maximum                   | 7.6+, 62.4+       | 8.3+,54.5+        |
| Rate (%) of 0S                    |                   |                   |
| ≥12 monthsa                       | 94.8              | 100.0             |
| 95% CIc                           | (80.7, 98.7)      | (NE, NE)          |
| Duration of OS follow-up (months) |                   |                   |
| Mediana                           | 36.90             | 38.74             |
| 25th, 75th percentiles            | 21.5,49.3         | 17.1, 47.2        |

Abbreviations: CI = confidence interval; N = number of patients; NE = not estimable; OS = overall survival; RAI = radioactive iodine; RET =REarranged during Transfection; TC = thyroid cancer; TrtSysNaive = patients not previously treated with systemic therapy other than RAI.

b 95% CI was calculated using Brookmeyer and Crowley method.

95% CI was calculated using Greenwood's formula.

Note: + = censored observation.

## Time to Response and Time to Best Response DCO 21 June 2021

For the 15 responders in the RET fusion-positive TC Primary Efficacy Analysis Set (TC:TrtSysNaïve), the median TTR and TTBR by IRC assessment was 1.8 and 3.6 months, respectively.

<div style=\"page-break-after: always\"></div>

Table 20. Time to Response and Time to Best Response Based on IRC and Investigator Assessments RET Fusion-Positive TC Primary Efficacy Analysis Set

<!-- image -->

|                                                      | TC:IrtSysNaive N=16   | TC:IrtSysNaive N=16     |
|------------------------------------------------------|-----------------------|-------------------------|
|                                                      | IRC Assessment        | Investigator Assessment |
| Patients with best response of confirmed CR or PR, n | 15                    | 13                      |
| Time to response (months)*                           |                       |                         |
| Median                                               | 1.8                   | 1.8                     |
| 25th, 75th percentiles                               | 1.8, 4.6              | 1.8, 1.9                |
| Min-max                                              | 1.4-7.2               | 1.4-5.5                 |
| Time to response, n (96)                             |                       |                         |
| 2months                                              | 10 (66.7)             | 10 (76.9)               |
| 22 to c4 months                                      | 1 (6.7)               | 1 (7.7)                 |
| 24 months                                            | 4 (26.7)              | 2 (15.4)                |
| Time to best response (months)b                      |                       |                         |
| Median                                               | 3.6                   | 1.9                     |
| 25th,75th percentiles                                | 1.8,5.5               | 1.8,5.5                 |
| Min-max                                              | 1.7-13.8              | 1.4-14.0                |
| Time to best response, n (96)                        |                       |                         |
| 2 monihs                                             | 7 (46.7)              | 8 (61.5)                |
| 22 to =4 months                                      | 3 (20.0)              | 0 (0.0)                 |
| 24 months                                            | 5 (33.3)              | 5 (38.5)                |

- Abbreviations:CR=complete response;IRC=Independent Review Comumittee;max=maximum;min= minimum; N = mumber of patienis; n = number of patients in the specific category; PR = partial response; RAI = radioactive iodine; RET = REarranged during Transfection; TC = thyroid cancer; IC:TriSysNaire = Patients Not Previously Treated with Systemic Therapy other than RAI.
- Time to response is defined as the number of months elapsed between the date of the first dose of selpercatinib and the first documentation of overall response (CR or PR whichever occured earlier) that was subsequently confirmed.
- Time to best response is defined as the number of months elapsed between the date of the first dose of selpercatinib and the first documentation of CR (if the patient's best response is confirmed CR) or PR (if the patient's best response is confimmed PR) that was subsequently confirmed.

## Ancillary analyses

## Subgroup analysis

The below table summarises the ORR and DoR by RET fusion partner genes based on IRC assessments in the TC:TrtSysNaïve population treated until 15 December 2020.

<div style=\"page-break-after: always\"></div>

Table 21. Objective Response Rate and Duration of Response by RET Fusion Partner Gene Based on IRC Assessments

|                    |              | ORR                        | ORR         | DoR\"            | DoR\"     |
|--------------------|--------------|----------------------------|-------------|-----------------|----------|
|                    | Patients (n) | Number of Responders (96)b | 10 9696     | Median (months) | 9596 CI  |
| RETFusion Partners | 16           | 15 (93.8)                  | 69.8,99.8   | NR.             | 19.4, NE |
| CCDC6              | 9            | 9 (100.0)                  | 66.4, 100.0 | NR.             | 19.4, NE |
| NC0A4              | 5            | 4 (80.0)                   | 28.4, 99.5  | NR.             | 14.8, NE |
| Other              | 2            | 2 (PR, PR)                 | NA          | NR.             | NE, NE   |

Abbreviations: CI=confidence interval; DoR =duration of response: IRC =Independent Review Comminee: PR = partial response, NA = not applicable, NE = not ewaluable; NR = not reached; ORR = objective response rate; RET =REamanged during Transfection.

- Estimate based on the Kaplan-Meier method.

b Perceutage is not calculated when patients (n) ≤2 and best overall response is shown instead.

Note: Percentage is calculated based on the number of patients in the denominator.

Eligible patients are defined aspatients treated on or before 15 December 2020.

Other:KIAA1217,TRIM24

<div style=\"page-break-after: always\"></div>

Figure 6. Forest Plot of Objective Response Rate in Special/Subgroup Populations Based on IRC Assessments Efficacy Eligible Subjects of RET Fusion Thyroid treated until 15 December 2020.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 7. Forest Plot of Objective Response Rate in Special/Subgroup Populations Based on Investigator Assessments Efficacy Eligible Subjects of RET Fusion Thyroid treated until 15 December 2020.

<!-- image -->

## Supportive Efficacy Analysis Set from TC:TrtSys patients

Patients with RET Fusion-Positive TC Previously Treated with Systemic Therapy Other Than RAI

At the DCO 13 January 2023 TC:TrtSys patients (N = 41) had an ORR of 85.4% (95% CI: 70.8, 94.4). With a median response follow-up time of 33.9 months for the 35 responders, the median DOR estimated by the IRC was 26.7 months (95% CI: 12.1, NE), which demonstrates that selpercatinib provides robust and durable responses. The estimated rate of DOR was 71.7% at 12 months and 50.7% at 24 months. The  median  time  to  response  by  the  IRC  assessment  was  1.8  months,  with  71.4%  of  patients demonstrating an initial response at the first post-baseline radiographic assessment.

The median PFS estimate reached 27.4 months (95% CI: 14.5, NE), with a median follow-up of 30.4 months. The median OS was not reached.

<div style=\"page-break-after: always\"></div>

## Study: LIBRETTO-121

This is a multicenter, open-label, Phase 1/2 study in paediatric patients (paediatric patients ≥ 12 years of age and ≤ 21 years) with an advanced solid or primary CNS tumor harboring an activating RET alteration.

## Objectives and endpoints

Table 1 summarizes the objectives and endpoints for the Phase 1/2 part of the study (interim report as per Protocol Version 7.0)

Table 22 Objectives and Endpoints

| Objectives                                                                                                                                                                                                                                                                                                            | Endpoints                                                                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase 1                                                                                                                                                                                                                                                                                                               | Phase 1                                                                                                                                                          |
| Primary To determine the safety,includingDLTs,of the oral RET inhibitor selpercatinib in pediatric patients with an advanced solid or primary CNS tumor harboring an activating RET alteration                                                                                                                        | Frequency, severity, and relatedness of TEAEs andSAEs,includingDLTs in pediatric patients receiving selpercatinib                                                |
| Secondary                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                  |
| To characterize the PK properties of selpercatinibinpediatricpatientswith advanced solid, or primary CNS tumors harboring an activating RET alteration                                                                                                                                                                | Plasma concentrations of selpercatinib and PK parameters, including, but not limited to AUC(0-24), Cmas, tmas, degree of accumulation, andothercharacterizations |
| To identify the MTD and/or the appropriate dose of selpercatinib for further clinical investigation in this patient population                                                                                                                                                                                        | The MTD and/or the RP2D of selpercatinib in the pediatric patients                                                                                               |
| To describe the antitumor activity of selpercatinib in pediatric patients with advanced solid or primary CNS tumors harboring an activating RET alteration                                                                                                                                                            | ORR andCBRbasedon RECIST 1.1 orRANO as appropriate to tumor type as determined by anIRC and treatinginvestigator                                                 |
| Phase 2                                                                                                                                                                                                                                                                                                               | Phase 2                                                                                                                                                          |
| Primary                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                  |
| To determine the ORR as determined by an IRC and measured by the proportion of patients with best overall confirmed response of CR or PR by RECIST 1.1, or RANO criteria, as appropriate, following treatment with selpercatinib in pediatric patients with an advanced cancer harboring an activating RET alteration | ORRbasedonRECIST 1.1orRANO as appropriate to tumor type as determined by an IRC                                                                                  |
| Secondary                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                  |
| To determine the following in patients with advanced cancer harboring an activating RET alteration: ORR based on the treating investigator's fesponse assessment using RECIST 1.1 or RANO criteria, as appropriate to tumof type                                                                                      | ORR based on RECIST 1.1 or RANO as appropriate to tumor type per the treating investigator's response assessment                                                 |
| DOR in patients with best overall response ofCRorPR as determined by1) anIRC and 2) the treating investigator                                                                                                                                                                                                         | DOR (IRC and treating investigator)                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Endpoints                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PFS following initiation of selpercatinib by 1) an IRC and 2) the treating investigator OSfollowinginitiation of selpercatinib ToevaluatetheCBRbasedonthe proportion of patients with best overall fesponse of CR, PR, or SD lasting 16 of more weeks following initiation of selpercatinib as determined by 1) an IRC and 2) the treating investigator To assess the safety profile and tolerability of selpercatinib To characterize the PK properties of selpercatinib in pediatric patients | PFS (IRC and treating investigator) OS CBR (IRC and treating investigator) Frequency, severity, and relatedness of TEAEs and SAEs, changes in hematology and blood chemistry values, and assessments of physical examinations, vital signs, and ECGs Plasma concentrations of selpercatinib and PK parameters, including, but not limited to AUC(0-24), Cmas, tmax, degree of accumulation, and other characterizations |

## Main Inclusion/Exclusion Criteria

To be eligible for the study, patients must have

- been at least 6 months of age and 21 years of age or below at C1D1 with a locally advanced or metastatic solid or primary CNS tumor that had relapsed, progressed, or was nonresponsive to available therapies and/or for which no standard or available systemic curative therapy exists
- evidence of an activating RET gene alteration in tumor and/or blood (for example, gene rearrangement and/or mutation, excluding synonymous, frameshift, or nonsense mutations) as identified through molecular assays, as performed for clinical evaluation
- had measurable or nonmeasurable but evaluable disease
- had a Karnofsky (patients 16 years and older) or Lansky (patients younger than 16 years) performance score of at least 50
- had adequate hematologic status, and/or
- had adequate renal, hepatic/pancreatic function.

Patients were not eligible to be included in the study, if they

- underwent major surgery within 2 weeks prior to C1D1, and/or
- had active or prior history of events that might put patients at increased risk when taking selpercatinib, such as
- ◊ known cardiac disease
- ◊ uncontrolled infection
- ◊ malabsorption syndrome or gastrointestinal absorption of the drug
- ◊ uncontrolled hypotension or hypertension
- ◊ uncontrolled symptomatic hypothyroidism or hyperthyroidism
- ◊ uncontrolled symptomatic hyperglycemia or hypocalcemia, or
- ◊ hypersensitive to any of the components of the investigational agent, selpercatinib or OraSweet® SF and OraPlus®.

## Disposition of Participants

<div style=\"page-break-after: always\"></div>

Table 23. Summary of Study and Treatment Disposition By Tumor Type All Enrolled Population Data Cutoff: 13 January 2023

| StudyDisposition                      | Overall Population (N =31) n (%)   | MTC Population (N =14) n (%)   | PTC Population (N =10) n (%)   | Other (N=3) n (%)              |
|---------------------------------------|------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Patients enrolled                     | 31                                 | 14                             | 10                             | 3                              |
| Screen failure                        | 4                                  | 0                              | 0                              | 0                              |
| Subjects treated                      | 27 (100.0)                         | 14 (100.0)                     | 10 (100.0)                     | 3 (100.0)                      |
| Treatment status                      |                                    |                                |                                |                                |
| On treatment                          | 22 (81.5)                          | 13 (19.2)                      | 9 (90.0)                       | 0                              |
| Discontinued                          | 5 (18.5)                           | 1 (7.1)                        | 1 (10.0)                       | 3 (100.0)                      |
| Reasonfortreatment discontinuation    | Reasonfortreatment discontinuation |                                |                                |                                |
| Progressive disease                   | 3 (11.1)                           | 0                              | 0                              | 3 (100.0)                      |
| Pregnancy                             | 1 (3.7)                            | 0                              | 1 (10.0)                       | 0                              |
| Significant noncompliance to protocol | 1 (3.7)                            | 1 (7.1)                        | 0                              | 0                              |
| Study status                          | Study status                       |                                |                                |                                |
| On study                              | 24 (88.9)                          | 14 (100.0)                     | 10 (100.0)                     | 0                              |
| Discontinued                          | 3 (11.1)                           | 0                              | 0                              | 3 (100.0)                      |
| Reasonsforstudydiscontinuation        | Reasonsforstudydiscontinuation     | Reasonsforstudydiscontinuation | Reasonsforstudydiscontinuation | Reasonsforstudydiscontinuation |
| Death                                 | 3 (11.1)                           | 0                              | 0                              | 3 (100.0)                      |

Abbreviations: MTC = medullary thyroid cancer; n = number of patients in the specific category; N = number of patients; PTC = papillary thyroid cancer.

## Number of Participants

Table 24 provides the number of participants included in each analysis population.

Table 24. Analysis Populations for Study LIBRETTO-121

| Population          | Description                                                                                         |   N |
|---------------------|-----------------------------------------------------------------------------------------------------|-----|
| Entered             | Patientswhosignedtheinformedconsent/assentdocument                                                  |  31 |
| Safety and Efficacy | Allpatientswhoreceivedatleast1doseofselpercatinib                                                   |  27 |
| MTC                 | IncludespatientswithRET-mutantMTC                                                                   |  14 |
| PTC                 | IncludespatientswithRET-fusionPTC                                                                   |  10 |
| Other               | IncludespatientswithRET-alteredosteosarcoma,malignant peripheralnervesheathtumorandrhabdomyosarcoma |   3 |

Abbreviations: MTC=medullary thyroid cancer;N=number ofpatients in the analysis population;PTC =papillary thyroidcancer;RET=REarrangedduringTransfection.

## Demographic and Other Baseline Characteristics

Table 25. Summary of Patient Demographics by Tumor Type Safety Analysis Population Data Cutoff: 13 January 2023

| Parameter             | Overall Population (N = 27)   | MTCPopulation (N =14)   | PTCPopulation (N =10)   | Other (N = 3)   |
|-----------------------|-------------------------------|-------------------------|-------------------------|-----------------|
| Age (years, n)        |                               |                         |                         |                 |
| Median                | 13.0                          | 14.0                    | 13.5                    | 13.0            |
| Min-Max               | 2-20                          | 2-20                    | 12-20                   | 5-15            |
| Overallagegroup,n (%) |                               |                         |                         |                 |
| 6months-<2years       | 0                             | 0                       | 0                       | 0               |
| 2-<12years            | 6 (22.2)                      | 5 (35.7)                | 0                       | 1 (33.3)        |
| 12-<18years           | 15 (55.6)                     | 5 (35.7)                | 8 (80.0)                | 2 (66.7)        |
| 18-21years            | 6 (22.2)                      | 4 (28.6)                | 2 (20.0)                | 0               |
| Sex, n (%)            |                               |                         |                         |                 |
| Male                  | 16 (59.3)                     | 9 (64.3)                | 6 (60.0)                | 1 (33.3)        |

<div style=\"page-break-after: always\"></div>

| Parameter                         | Overall Population (N = 27)   | MTC Population (N =14)   | PIC Population (N =10)   | Other (N= 3)   |
|-----------------------------------|-------------------------------|--------------------------|--------------------------|----------------|
| Female                            | 11 (40.7)                     | 5 (35.7)                 | 4 (40.0)                 | 2 (66.7)       |
| Race, n (%)                       |                               |                          |                          |                |
| White                             | 14 (51.9)                     | 10 (71.4)                | 4 (40.0)                 | 0              |
| Black or African American         | 3 (11.1)                      | 2 (14.3)                 | 0                        | 1 (33.3)       |
| Asian                             | 7 (25.9)                      | 0                        | 5 (50.0)                 | 2 (66.7)       |
| Other                             | 2 (7.4)                       | 1 (7.1)                  | 1 (10.0)                 | 0              |
| Missing                           | 1 (3.7)                       | 1 (7.1)                  | 0                        | 0              |
| Ethnicity, n (%o)                 |                               |                          |                          |                |
| Hispanicor Latino                 | 5 (18.5)                      | 2 (14.3)                 | 3 (30.0)                 | 0              |
| Not Hispanic or Latino            | 20 (74.1)                     | 10 (71.4)                | 7 (70.0)                 | 3 (100.0)      |
| Unknown                           | 1 (3.7)                       | 1 (7.1)                  | 0                        | 0              |
| Missing                           | 1 (3.7)                       | 1 (7.1)                  | 0                        | 0              |
| Body weight (kg)                  |                               |                          |                          |                |
| Mean                              | 48.3                          | 44.2                     | 54.6                     | 46.8           |
| Median                            | 48.5                          | 46.1                     | 48.4                     | 54.7           |
| Min-Max                           | 10-98                         | 10-93                    | 43-98                    | 17-69          |
| Height (cm)                       |                               |                          |                          |                |
| Mean (SD)                         | 155.0 (25.90)                 | 153.6 (33.29)            | 160.6 (10.05)            | 142.6 (25.83)  |
| Median                            | 165.0                         | 169.9                    | 162.5                    | 148.0          |
| Min-Max                           | 75-191                        | 75-191                   | 142-176                  | 115-165        |
| BodySurfaceArea (m)               |                               |                          |                          |                |
| Mean (SD)                         | 1.4 (0.42)                    | 1.4 (0.49)               | 1.5 (0.26)               | 1.3 (0.54)     |
| Median                            | 1.5                           | 1.5                      | 1.5                      | 1.5            |
| Min-Max                           | 0-2                           | 0-2                      | 1-2                      | 1-2            |
| Karnofsky/Lansky PS Status, n (%) |                               |                          |                          |                |
| Mean (SD)                         | 89.3 (16.39)                  | 88.6 (15.62)             | 93.0 (14.94)             | 80.0 (26.46)   |
| Median                            | 100.0                         | 100.0                    | 100.0                    | 90.0           |
| Min-Max                           | 50-100                        | 60-100                   | 60-100                   | 50-100         |

Abbreviations:Max=maximum;Min=minimum;MTC=medullary thyroid cancer;n=numberofsubjectsin the specified category; N = number of subjects in safety population; PS = performance status; PTC = papillary thyroid cancer; SD = standard deviation.

<div style=\"page-break-after: always\"></div>

Table 26. Baseline Disease Characteristics by Tumor Type Safety Analysis Population Data Cutoff: 13 January 2023

| Parameter                            | Overall Population (N= 27) n (%)   | MTC Population (N =14) n (%)   | PTC Population (N =10) n (%)   | Other (N=3) n (%)   |
|--------------------------------------|------------------------------------|--------------------------------|--------------------------------|---------------------|
| Stage at initial diagnosis, n (%)    |                                    |                                |                                |                     |
| IB                                   | 1 (3.7)                            | 1 (7.1)                        | 0                              | 0                   |
| II                                   | 4 (14.8)                           | 0                              | 4 (40.0)                       | 0                   |
| III                                  | 2 (7.4)                            | 2 (14.3)                       | 0                              | 0                   |
| IV                                   | 18 (66.7)                          | 10 (71.4)                      | 5 (50.0)                       | 3 (100.0)           |
| Missing                              | 2 (7.4)                            | 1 (7.1)                        | 1 (10.0)                       | 0                   |
| Timesinceinitial diagnosis,months    |                                    |                                |                                |                     |
| Median                               | 13.50                              | 8.65                           | 21.40                          | 13.50               |
| Range                                | 0.1-114.5                          | 0.1-114.5                      | 1.0-68.9                       | 2.5-40.9            |
| Time since metastatic disease,months |                                    |                                |                                |                     |
| N                                    | 22                                 | 10                             | 10                             | 2                   |
| Median                               | 8.55                               | 6.70                           | 12.55                          | 22.40               |
| Range                                | 0.1-71.4                           | 0.1-71.4                       | 1.0-68.9                       | 4.3-40.5            |
| Grade, n (%)                         |                                    |                                |                                |                     |
| Well differentiated                  | 6 (22.2)                           | 0                              | 6 (60.0)                       | 0                   |
| Poorly differentiated                | 4 (14.8)                           | 2 (14.3)                       | 1 (10.0)                       | 1 (33.3)            |
| Not applicable                       | 4 (14.8)                           | 3 (21.4)                       | 0                              | 1 (33.3)            |
| Unknown                              | 12 (44.4)                          | 8 (57.1)                       | 3 (30.0)                       | 1 (33.3)            |

Abbreviations: MTC = medullary thyroid cancer; n = number of patients in the specific category; N = number of patients; PTC = papillary thyroid cancer.

## Efficacy Results

<div style=\"page-break-after: always\"></div>

Table 27.Response Results Based on IRC Assessment RET Fusion-Positive TC Efficacy Analysis Set Study LIBRETTO-121

<!-- image -->

|                                                           | Overall Population N=27   | Overall Population N=27   | MIC Population N=14   | MIC Population N=14     | PIC Population N=10   | PIC Population N=10     |
|-----------------------------------------------------------|---------------------------|---------------------------|-----------------------|-------------------------|-----------------------|-------------------------|
|                                                           | IRC Assessment            | Investigator Assessment   | IRC Assessment        | Investigator Assessment | IRC Assessment        | Investigator Assessment |
| Objective response ratea                                  |                           |                           |                       |                         |                       |                         |
| n (%)                                                     | 12 (44.4)                 | 10 (37.0)                 | 6 (42.9)              | 5 (35.7)                | 6 (60.0)              | 5 (50.0)                |
| 95% CIb                                                   | 25.5, 64.7                | 19.4, 57.6                | 17.7, 71.1            | 12.8, 64.9              | 26.2, 87.8            | 18.7, 81.3              |
| Best overall response, n (%)                              |                           |                           |                       |                         |                       |                         |
| Complete response (CR)                                    | 4 (14.8)                  | 4 (14.8)                  | 1 (7.1)               | 2 (14.3)                | 3 (30.0)              | 2 (20.0)                |
| Partial response (PR)                                     | 8 (29.6)                  | 6 (22.2)                  | 5 (35.7)              | 3 (21.4)                | 3 (30.0)              | 3 (30.0)                |
| Stable disease (SD)                                       | 8 (29.6)                  | 13 (48.1)                 | 4 (28.6)              | 8 (57.1)                | 4 (40.0)              | 5 (50.0)                |
| SD16+c                                                    | 8 (29.6)                  | 13 (48.1)                 | 4 (28.6)              | 8 (57.1)                | 4 (40.0)              | 5 (50.0)                |
| Progressive disease (PD)                                  | 1 (3.7)                   | 2 (7.4)                   | 0                     | 0                       | 0                     | 0                       |
| Not evaluable                                             | 5 (18.5)                  | 2 (7.4)                   | 3 (21.4)              | 1 (7.1)                 | 0                     | 0                       |
| Clinical benefit rate (CR +uCRc+PR + uPRc+SD16+c weeksc)d |                           |                           |                       |                         |                       |                         |
| n (%)                                                     | 21 (77.8)                 | 23 (85.2)                 | 11 (78.6)             | 13 (92.9)               | 10 (100.0)            | 10 (100.0)              |
| 95% CIb                                                   | 57.7,91.4                 | 66.3, 95.8                | 49.2, 95.3            | 66.1, 99.8              | 69.2,100.0            | 69.2,100.0              |
| Duration of responsef,g                                   |                           |                           |                       |                         |                       |                         |
| Responders, n                                             | 12                        | 10                        | 6                     | 5                       | 6                     | 5                       |
| Median in months (95% CI)                                 | NE (NE, NE)               | NE (NE, NE)               | NE (NE, NE)           | NE (NE, NE)             | NE (NE. NE)           | NE (NE, NE)             |
| Duration ofresponse (n, %)                                |                           |                           |                       |                         |                       |                         |
| <6 months                                                 | 0                         | 0                         | 0                     | 0                       | 0                     | 0                       |
| 26 to 12 months                                           | 1 (8.3)                   | 1 (10.0)                  | 0                     | 1 (20.0)                | 1 (16.7)              | 0                       |
| ≥12 to 18 months                                          | 4 (33.3)                  | 2 (20.0)                  | 2 (33.3)              | 0                       | 2 (33.3)              | 2 (40.0)                |
| ≥18to 24 months                                           | 2 (16.7)                  | 4 (40.0)                  | 0                     | 3 (60.0)                | 2 (33.3)              | 1 (20.0)                |
| ≥24 months                                                | 5 (41.7)                  | 3 (30.0)                  | 4 (66.7)              | 1 (20.0)                | 1 (16.7)              | 2 (40.0)                |
| Censored n (%)g                                           | 12 (100.0)                | 10 (100.0)                | 6 (100.0)             | 5 (100.0)               | 6 (100.0)             | 5 (100.0)               |
| Reason censored                                           |                           |                           |                       |                         |                       |                         |
| Alive without documented disease progression              | 12 (100.0)                | 10 (100.0)                | 6 (100.0)             | 5 (100.0)               | 6 (100.0)             | 5 (100.0)               |
| Rate (%)of duration                                       |                           |                           |                       |                         |                       |                         |

<div style=\"page-break-after: always\"></div>

|                                 | Overall Population N= 27   | Overall Population N= 27   | MTC Population N = 14   | MTC Population N = 14   | PTC Population N = 10   | PTC Population N = 10   |
|---------------------------------|----------------------------|----------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                 | IRC Assessment             | Investigator Assessment    | IRC Assessment          | Investigator Assessment | IRC Assessment          | Investigator Assessment |
| of responsee,f                  |                            |                            |                         |                         |                         |                         |
| ≥6 to 12 months (95% CI)        | 100.0 (NE, NE)             | 100.0 (NE, NE)             | 100.0 (NE, NE)          | 100.0 (NE. NE)          | 100.0 (NE, NE)          | 100.0 (NE, NE)          |
| ≥12 to 18 months (95% CI)       | 100.0 (NE, NE)             | 100.0 (NE, NE)             | 100.0 (NE, NE)          | 100.0 (NE, NE)          | 100.0 (NE, NE)          | 100.0 (NE, NE)          |
| ≥24 months (95% CI)             | 100.0 (NE, NE)             | 100.0 (NE, NE)             | 100.0 (NE, NE)          | 100.0 (NE, NE)          | 100.0 (NE, NE)          | 100.0 (NE, NE)          |
| Duration of follow-up (months)e |                            |                            |                         |                         |                         |                         |
| Median                          | 18.69                      | 20.30                      | 25.64                   | 20.37                   | 17.20                   | 18.66                   |
| 25th, 75th percentile           | 15.7, 26.0                 | 15.0, 24.9                 | 15.7, 27.9              | 20.2,23.3               | 15.7, 18.7              | 15.0, 24.9              |

Abbreviations:CI=confidenceinterval;CR=completeresponse;IRC=independentreviewcommittee;

MTC = medullary thyroid cancer; n = number of patients per category; N =number of patients in population; NE =not evaluable; PD =progressive disease; PR =partial response; PTC =papillary thyroid cancer; RET = Rearranged during Transfection; SD = stable disease; SD16+ = stable disease lasting 16 or more weeks; uCR = unconfirmedCR;uPR=unconfirmedPR

- Objective response rate (%) is defined as the proportion of patients with best overall response of confirmed CR or PR. Response was confirmed by a repeat assessment no less than 28 days.
- 95% confidence interval was calculated using Clopper-Pearson method.
- Indicates uPR,uCR, SD1asting≥16weeks following initiation of selpercatinib until the criteria for disease progression was first met.
- PR, or stable disease lasting 16 or more weeks for patients with uCR*, uPR*, or SD*. Stable disease was measured from the date for first dose of selpercatinib, until the criteria for disease progression was first met.
- e Estimate based on Kaplan-Meier method.
- f95% confidence interval was calculated using Greenwood's formula.
- g Status as of the patient's last disease assessment on or before cutoff date
- *Indicates uPR, SD lasting &gt;=16weeks following initiation of selpercatinib until the criteria for disease progression was first met.

## Progression-Free Survival

<div style=\"page-break-after: always\"></div>

Table 28. Progression-Free Survival by Tumor Type Safety Analysis Population Data Cutoff: 13 January 2023

<!-- image -->

| Status                          | Overall Population N=27   | MTC Population N =14   | PTC Population N =10   |
|---------------------------------|---------------------------|------------------------|------------------------|
| Survival status n (%)           |                           |                        |                        |
| Died                            | 3 (11.1)                  | 0                      | 0                      |
| Censored                        | 24 (88.9)                 | 14 (100.0)             | 10 (100.0)             |
| Overall survival (months)a,b    |                           |                        |                        |
| Median                          | NE                        | NE                     | NE                     |
| 95% CIfor median                | NE, NE                    | NE, NE                 | NE, NE                 |
| Min, max                        | 0.5, 40.8+                | 5.0+,40.8+             | 4.4+, 30.9+            |
| Duration of follow-up (months)a |                           |                        |                        |
| Median                          | 21.32                     | 29.95                  | 20.21                  |
| 25th, 75th percentiles          | 11.4, 31.2                | 11.4, 36.1             | 9.8, 21.7              |
| Rate (%) of overall survivala,c |                           |                        |                        |
| 6 months or more (95% C1)       | 96.3 (76.5,99.5)          | 100.0 (NE, NE)         | 100.0 (NE, NE)         |
| 12 months of more (95% CI       | 87.7 (66.2,95.9)          | 100.0 (NE, NE)         | 100.0 (NE, NE)         |
| 24 months of more (95% CI)      | 87.7(66.2,95.9)           | 100.0 (NE, NE)         | 100.0 (NE, NE)         |

Abbreviations: CI = confidence interval; IRC = independent review committee; max = maximum; min = minimum; MTC = medullary thyroid cancer; n = number of patients in the specific category; N = number of patients; NE = not estimable; PTC = papillary thyroid cancer.

- Estimate based on Kaplan-Meier method. NE =Not estimable. + = Censored observation.
- b 95% Confidence interval was calculated using Brookmeyer and Crowley method.

95% Confidence interval was calculated using Greenwood's formula.

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 29. Summary of Efficacy for trial LIBRETTO-001 (LOXO-RET-17001 (J2G-OX-JZJA); Data Cutoff: 13 Jan 2023) - Effects Table for Selpercatinib for the Treatment of Patients with Advanced RET FusionPositive Thyroid Cancer

| Title: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer, and Other Tumours with RET Activation (LIBRETTO-001)   | Title: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer, and Other Tumours with RET Activation (LIBRETTO-001)                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                 | LOXO-RET-17001 (J2G-OX-JZJA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                           | This is a multicentre, multi-country, open-label, Phase 1/2 study in participants with advanced solid tumours, including REarranged during Transfection ( RET ) fusion-positive solid tumours, RET -mutant medullary thyroid cancer, and other tumours with RET activation (for example, mutations in other tumour types or other evidence of RET activation). This study is ongoing and includes 2 parts: Phase 1 (dose escalation and dose expansion) and Phase 2 (dose expansion). The primary efficacy analysis set includes patients with thyroid cancer who have not been previously treated with systemic therapy other than radioactive iodine. |

<div style=\"page-break-after: always\"></div>

|                                           | Duration of main phase:                                                                                                                                   | Duration of main phase:                                                                                                                                   | The study is ongoing. Patients are to be treated until there is evidence of progressive disease, unacceptable toxicity, or other reason for treatment discontinuation.                                                                                                                                                                 |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                                | Exploratory: single-arm treatment. For Cohort 2 (patients with RET fusion- positive solid tumours without prior standard 1st-line therapy), a true ORR of | Exploratory: single-arm treatment. For Cohort 2 (patients with RET fusion- positive solid tumours without prior standard 1st-line therapy), a true ORR of | Exploratory: single-arm treatment. For Cohort 2 (patients with RET fusion- positive solid tumours without prior standard 1st-line therapy), a true ORR of                                                                                                                                                                              |
| Treatments groups                         | Selpercatinib                                                                                                                                             | Selpercatinib                                                                                                                                             | Phase 2: 160 mg twice daily TC:TrtSysNaïve: n=24                                                                                                                                                                                                                                                                                       |
| Endpoints and definitions                 | Primary endpoint                                                                                                                                          | ORR based on IRC assessment                                                                                                                               | The estimate of ORR will be calculated based on the maximum likelihood estimator (ie, crude proportion of patients with best overall response of CR or PR).                                                                                                                                                                            |
| Endpoints and definitions                 | Secondary endpoint                                                                                                                                        | ORR based on Investigator assessment                                                                                                                      | The estimate of ORR will be calculated based on the maximum likelihood estimator (ie, crude proportion of patients with best overall response of CR or PR).                                                                                                                                                                            |
| Endpoints and definitions                 | Secondary endpoint                                                                                                                                        | TTR based on IRC and Investigator assessment                                                                                                              | TTR is defined as the number of months elapsed between the date of the 1st dose of selpercatinib and the 1st documentation of objective response (CR or PR, whichever occurs earlier) that is subsequently confirmed.                                                                                                                  |
| Endpoints and definitions                 | Secondary endpoint                                                                                                                                        | TTBR based on IRC and Investigator assessment                                                                                                             | TTBR is defined as the number of months elapsed between the date of the 1st dose of selpercatinib and the 1st documentation of CR (if patient's best overall response is confirmed CR) or PR (if patient's best overall response is confirmed PR) that is subsequently confirmed.                                                      |
| Endpoints and definitions                 | Secondary endpoint                                                                                                                                        | DoR based on IRC and Investigator assessment                                                                                                              | DoR will be calculated for patients with CR or PR as their best overall response. For such patients, DoR is defined as the number of months from the start date of CR or PR (whichever response status is observed 1st) and subsequently confirmed, to the 1st date that recurrent or disease progression is objectively documented.   |
| Endpoints and definitions                 | Secondary endpoint                                                                                                                                        | PFS CBR based on IRC and Investigator assessment                                                                                                          | PFS is defined as the number of months elapsed between the date of the 1st dose of selpercatinib and the earliest date of documented disease progression or death (whatever the cause).                                                                                                                                                |
| Endpoints and definitions                 | Secondary endpoint                                                                                                                                        | OS                                                                                                                                                        | OS is defined as the number of months elapsed between the date of the 1st dose of selpercatinib and the date of death (whatever the cause). Patients who are alive or lost to follow-up as of the data cutoff date will be right-censored. The censoring date will be determined from the date the patient was last known to be alive. |
| Database lock                             | 13 January 2023                                                                                                                                           | 13 January 2023                                                                                                                                           | 13 January 2023                                                                                                                                                                                                                                                                                                                        |
| Results and Analysis Analysis description | Primary Analysis                                                                                                                                          | Primary Analysis                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description   | Patients with RET fusion-positive TC not previously treated with systemic therapy other than radioactive iodine Efficacy Data Set Data cutoff: 13 January 2023   | Patients with RET fusion-positive TC not previously treated with systemic therapy other than radioactive iodine Efficacy Data Set Data cutoff: 13 January 2023   | Patients with RET fusion-positive TC not previously treated with systemic therapy other than radioactive iodine Efficacy Data Set Data cutoff: 13 January 2023   |
|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                  | Selpercatinib                                                                                                                                                    | Selpercatinib                                                                                                                                                    |
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                  | IRC Assessment                                                                                                                                                   | Investigator Assessment                                                                                                                                          |
| Descriptive statistics and estimate variability  | Number of subjects                                                                                                                                               | N=24                                                                                                                                                             | N=24                                                                                                                                                             |
| Descriptive statistics and estimate variability  | Number of responders                                                                                                                                             | N=23                                                                                                                                                             | N=20                                                                                                                                                             |
| Descriptive statistics and estimate variability  | Objective response rate (95% CI) a,b                                                                                                                             | 95.8 (78.9, 99.9)                                                                                                                                                | 83.3 (62.6, 95.3)                                                                                                                                                |
| Descriptive statistics and estimate variability  | Clinical benefit rate (CR + PR + SD-16 weeks) g (95% CI) b                                                                                                       | 100.0 (85.8, 100.0)                                                                                                                                              | 100.0 (85.8, 100.0)                                                                                                                                              |
| Descriptive statistics and estimate variability  | Duration of response (months) - Median c,d (95% CI)                                                                                                              | NE (42.8, NE)                                                                                                                                                    | NE (29.7, NE)                                                                                                                                                    |
| Descriptive statistics and estimate variability  | Time to response (months) - Median e (25th, 75th percentiles)                                                                                                    | 1.87 (1.8, 3.6)                                                                                                                                                  | 1.87 (1.8, 3.6)                                                                                                                                                  |
| Descriptive statistics and estimate variability  | Time to best response (months) -                                                                                                                                 | 1.87                                                                                                                                                             | 1.87                                                                                                                                                             |
| Descriptive statistics and estimate variability  | Median f (25th, 75th percentiles)                                                                                                                                | (1.8, 3.7)                                                                                                                                                       | (1.8, 5.5)                                                                                                                                                       |
| Descriptive statistics and estimate variability  | Progression-free survival (months) - Median c,d (95% CI)                                                                                                         | NE (44.2, NE)                                                                                                                                                    | NE (31.0, NE)                                                                                                                                                    |
| Descriptive statistics and estimate variability  | Overall survival (months) - Median c,d (95% CI)                                                                                                                  | NE (NE, NE)                                                                                                                                                      |                                                                                                                                                                  |
| Descriptive statistics and estimate variability  | Duration of follow-up (months) - Median (95% CI)                                                                                                                 | 17.81 (9.3, 37.9)                                                                                                                                                | 31.74 (7.7, 39.6)                                                                                                                                                |

Table 30. A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Paediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours (LIBRETTO-121)

| Title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Paediatric Patients with Advanced RET -Altered Solid or Primary Central Nervous System Tumours (LIBRETTO-121)   | Title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Paediatric Patients with Advanced RET -Altered Solid or Primary Central Nervous System Tumours (LIBRETTO-121)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                               | LOXO-RET-18036 (J2G-OX-JZJJ)                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Design            | This is a multicentre, open-label, Phase 1/2 study in paediatric and adolescent patients with advanced solid or primary CNS tumours harbouring an activating RET alteration. Selpercatinib is administered as an oral liquid suspension or in capsule form BID, with dose escalation according to evaluations of safety, efficacy, and PK, with a body surface area-based dose in all cohorts. This study is ongoing and includes 2 parts: Phase 1 (dose escalation and dose expansion) and Phase 2 (dose expansion). The primary objective of the Phase 1 portion of LIBRETTO-121 was to determine the maximum tolerated dose and recommended Phase 2 dose of selpercatinib. The Phase 2 portion will open enrolment when the MTD/ RP2D is confirmed and will enrol patients into one of 4 cohorts. The primary objective of the Phase 2 portion is to determine the ORR based on RECIST 1.1 or RANO as appropriate to tumour type as determined by an IRC. The disease criteria for each cohort is as follows • Cohort 1: RET fusion-positive solid tumour (excluding CNS primary) with measurable disease • Cohort 2: RET -mutant MTC with measurable disease • Cohort 3: RET fusion-positive primary CNS tumour with measurable disease • Cohort 4: Any patient with RET mutation/alteration not fitting Cohort 1   | This is a multicentre, open-label, Phase 1/2 study in paediatric and adolescent patients with advanced solid or primary CNS tumours harbouring an activating RET alteration. Selpercatinib is administered as an oral liquid suspension or in capsule form BID, with dose escalation according to evaluations of safety, efficacy, and PK, with a body surface area-based dose in all cohorts. This study is ongoing and includes 2 parts: Phase 1 (dose escalation and dose expansion) and Phase 2 (dose expansion). The primary objective of the Phase 1 portion of LIBRETTO-121 was to determine the maximum tolerated dose and recommended Phase 2 dose of selpercatinib. The Phase 2 portion will open enrolment when the MTD/ RP2D is confirmed and will enrol patients into one of 4 cohorts. The primary objective of the Phase 2 portion is to determine the ORR based on RECIST 1.1 or RANO as appropriate to tumour type as determined by an IRC. The disease criteria for each cohort is as follows • Cohort 1: RET fusion-positive solid tumour (excluding CNS primary) with measurable disease • Cohort 2: RET -mutant MTC with measurable disease • Cohort 3: RET fusion-positive primary CNS tumour with measurable disease • Cohort 4: Any patient with RET mutation/alteration not fitting Cohort 1   | This is a multicentre, open-label, Phase 1/2 study in paediatric and adolescent patients with advanced solid or primary CNS tumours harbouring an activating RET alteration. Selpercatinib is administered as an oral liquid suspension or in capsule form BID, with dose escalation according to evaluations of safety, efficacy, and PK, with a body surface area-based dose in all cohorts. This study is ongoing and includes 2 parts: Phase 1 (dose escalation and dose expansion) and Phase 2 (dose expansion). The primary objective of the Phase 1 portion of LIBRETTO-121 was to determine the maximum tolerated dose and recommended Phase 2 dose of selpercatinib. The Phase 2 portion will open enrolment when the MTD/ RP2D is confirmed and will enrol patients into one of 4 cohorts. The primary objective of the Phase 2 portion is to determine the ORR based on RECIST 1.1 or RANO as appropriate to tumour type as determined by an IRC. The disease criteria for each cohort is as follows • Cohort 1: RET fusion-positive solid tumour (excluding CNS primary) with measurable disease • Cohort 2: RET -mutant MTC with measurable disease • Cohort 3: RET fusion-positive primary CNS tumour with measurable disease • Cohort 4: Any patient with RET mutation/alteration not fitting Cohort 1   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design            | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | The study is ongoing. Patients are to be treated until there is evidence of until progressive disease, unacceptable toxicity, or other reason for treatment discontinuation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hypothesis        | Exploratory: For Cohorts 1 and 2, a sample size of 20 patients is estimated to provide approximately 75% power to achieve a lower boundary of a 2-sided 95% exact binomial CI about the estimated ORR that exceeds 20%. Ruling out a lower limit of 20% is considered clinically meaningful in patients who have limited treatment options for their advancing disease. Cohorts 3-4 are anticipated to enrol too few patients to be powered for a formal statistical testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Exploratory: For Cohorts 1 and 2, a sample size of 20 patients is estimated to provide approximately 75% power to achieve a lower boundary of a 2-sided 95% exact binomial CI about the estimated ORR that exceeds 20%. Ruling out a lower limit of 20% is considered clinically meaningful in patients who have limited treatment options for their advancing disease. Cohorts 3-4 are anticipated to enrol too few patients to be powered for a formal statistical testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Exploratory: For Cohorts 1 and 2, a sample size of 20 patients is estimated to provide approximately 75% power to achieve a lower boundary of a 2-sided 95% exact binomial CI about the estimated ORR that exceeds 20%. Ruling out a lower limit of 20% is considered clinically meaningful in patients who have limited treatment options for their advancing disease. Cohorts 3-4 are anticipated to enrol too few patients to be powered for a formal statistical testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Treatments groups | Selpercatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Selpercatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Phase 2: 92 mg/m 2 BID Overall Population: n=27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                   | Primary endpoint (Phase 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | ORR based on IRC assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | The estimate of ORR will be calculated based on the maximum likelihood estimator (ie, crude proportion of patients with best overall response of CR or PR).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                   | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ORR and CBR based on IRC and Investigator assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | The estimate of ORR will be calculated based on the maximum likelihood estimator (ie, crude proportion of patients with best overall response of CR or PR).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                                                     | Secondary endpoint                                                                   | DoR based on IRC and Investigator assessment                                         | DoR will be calculated for patients with CR or PR as their best overall response. For such patients, DoR is defined as the number of months from the start date of CR or PR (whichever response status is observed 1st) and subsequently confirmed, to the 1st date                                                                    | DoR will be calculated for patients with CR or PR as their best overall response. For such patients, DoR is defined as the number of months from the start date of CR or PR (whichever response status is observed 1st) and subsequently confirmed, to the 1st date                                                                    |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                     | Secondary endpoint                                                                   | PFS based on IRC and Investigator assessment                                         | PFS is defined as the number of months elapsed between the date of the 1st dose of selpercatinib and the earliest date of documented disease progression or death (whatever the cause).                                                                                                                                                | PFS is defined as the number of months elapsed between the date of the 1st dose of selpercatinib and the earliest date of documented disease progression or death (whatever the cause).                                                                                                                                                |
|                                                                     | Secondary endpoint                                                                   | OS                                                                                   | OS is defined as the number of months elapsed between the date of the 1st dose of selpercatinib and the date of death (whatever the cause). Patients who are alive or lost to follow-up as of the data cutoff date will be right-censored. The censoring date will be determined from the date the patient was last known to be alive. | OS is defined as the number of months elapsed between the date of the 1st dose of selpercatinib and the date of death (whatever the cause). Patients who are alive or lost to follow-up as of the data cutoff date will be right-censored. The censoring date will be determined from the date the patient was last known to be alive. |
| Database lock                                                       | 13 January 2023                                                                      |                                                                                      |                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                        |
| Results and Analysis                                                |                                                                                      |                                                                                      |                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                        |
| Analysis description Analysis population and time point description | Primary Analysis Paediatric and tumours harbouring                                   | adolescent patients an activating                                                    | advanced solid or alteration                                                                                                                                                                                                                                                                                                           | primary CNS                                                                                                                                                                                                                                                                                                                            |
| estimate variability                                                |                                                                                      |                                                                                      |                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and                                          |                                                                                      |                                                                                      |                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                        |
|                                                                     | Data cutoff: 13 January 2023                                                         | Data cutoff: 13 January 2023                                                         | Data cutoff: 13 January 2023                                                                                                                                                                                                                                                                                                           | Data cutoff: 13 January 2023                                                                                                                                                                                                                                                                                                           |
|                                                                     | Treatment group                                                                      | Treatment group                                                                      | Selpercatinib                                                                                                                                                                                                                                                                                                                          | Selpercatinib                                                                                                                                                                                                                                                                                                                          |
|                                                                     |                                                                                      |                                                                                      | IRC Assessment                                                                                                                                                                                                                                                                                                                         | Investigator Assessment                                                                                                                                                                                                                                                                                                                |
|                                                                     | Number of responders, n (%)                                                          | Number of responders, n (%)                                                          | 12 44.4 (25.5, 64.7)                                                                                                                                                                                                                                                                                                                   | 10 37.0 (19.4, 57.6)                                                                                                                                                                                                                                                                                                                   |
|                                                                     | Objective response rate (95% CI) a,b Clinical benefit rate (CR + PR + SD-16 weeks) e | Objective response rate (95% CI) a,b Clinical benefit rate (CR + PR + SD-16 weeks) e | 77.8 (57.7, 91.4)                                                                                                                                                                                                                                                                                                                      | 85.2 (66.3, 95.8)                                                                                                                                                                                                                                                                                                                      |
|                                                                     | Duration of response - Median c,d (95% CI)                                           | Duration of response - Median c,d (95% CI)                                           | NE (NE, NE)                                                                                                                                                                                                                                                                                                                            | NE (NE, NE)                                                                                                                                                                                                                                                                                                                            |
|                                                                     | Progression-free survival (months) Median c,d (95% CI)                               | Progression-free survival (months) Median c,d (95% CI)                               | NE (NE, NE)                                                                                                                                                                                                                                                                                                                            | NE (NE, NE)                                                                                                                                                                                                                                                                                                                            |
|                                                                     | Overall survival (months) - Median c,d (95% CI)                                      | Overall survival (months) - Median c,d (95% CI)                                      | NE (NE, NE)                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

- Abbreviations; BID = twice daily; CI = confidence interval; CNS = central nervous system CR = complete response; CBR =  clinical benefit rate; DoR = duration of response; IRC = Independent Review Committee; MTC = medullary thyroid cancer; MTD = maximum tolerated dose; N = total number of patients; n = number of patients in specific category; NE = not estimable; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PK = pharmacokinetics; PR = partial response; RANO = Response Assessment in Neuro-Oncology [group]; RECIST = Response Evaluation Criteria in Solid Tumours; RET = REarranged during Transfection; RP2D = recommended Phase 2 dose; SD = stable disease.
- a ORR is defined as the proportion of patients with BoR of confirmed CR or PR. Response was confirmed by a repeat assessment no less than 28 days.
- b 95% CI was calculated using the Clopper-Pearson method.
- c Estimate based on the Kaplan-Meier method.
- d    95% CI was calculated using the Brookmeyer and Crowley method.
- e Clinical benefit rate (%) is defined as the proportion of patients with BoR of confirmed CR, PR, or SD lasting 16, or more weeks. Duration of SD was measured from the date of the 1st dose of selpercatinib until the criteria for disease progression were 1st met.

Note: Eligible patients are treated on or before 13 January 2023. SD includes non-CR/non-PD for patients with nonmeasurable disease.

## 2.4.1. Paediatric Extrapolation

The justification of the extrapolation of Adult Data to Adolescents provided by the MAH is presented below:

RET is an oncogenic driver, and it is expected that therapeutic benefit of a selective RET inhibitor would be independent of age. For targeted cancer therapies, clinical outcomes for adolescent patients could be extrapolated from clinical trials with predominant enrolment of adult patients as the clinical outcomes are primarily related to the molecular basis of cancer, their associated pathways and PK responses. It is believed that medications designed for some cancers in adults may affect the same pathways in childhood and adolescent cancers (Paulson et al. 2019).

No patients with RET fusion-positive TC aged 18 years or less were identified for participation in LIBRETTO-001. Lilly is using an extrapolation approach from adults to adolescents aged 12 years and above based upon supportive evidence included from the available efficacy and safety data from LIBRETTO-121, and PK data from single-patient compassionate use protocols. A similar pattern of efficacy has been demonstrated with other agents that target oncogenic drivers. Related to this, it is important to note that the RET fusion partners identified in tumours from patients in LIBRETTO-121 were also identified in the tumours seen from LIBRETTO -001. As oncogenic RET fusions seem to be more prevalent in the paediatric DTC patients, treatment with a selective RET inhibitor has been of interest (Paulson et al. 2019). A similar approach was followed for the selpercatinib MTC indication, which has recently been authorised for the indication in adolescent patients aged 12 years and above based on data from 3 adolescent patients in LIBRETTO-001 and from extrapolation of adult data.

To enable an efficacy assessment based on the concept of extrapolation with supportive evidence from the available efficacy and safety analysis from LIBRETTO-121, it is necessary that there is an optimal consideration that the biology of disease, treatment (including targeted treatment), PK exposure, and unmet need are similar for adolescents and adults. The key considerations for justifying the extrapolation of adult data to adolescents aged 12 years and above have been presented as follows:

## Pharmacokinetics of selpercatinib in paediatric patients

Evidence from literature shows that adolescents and young adults most commonly demonstrate similar PK responses to adult patients (Bernstein 2011). Based on PK results of paediatric patients treated with selpercatinib in single-patient compassionate use protocols (Section 2.5.3), the PK of selpercatinib

<div style=\"page-break-after: always\"></div>

in paediatric patients are similar with the PK results observed in adult patients. No PK data have yet been analysed from LIBRETTO-121.

## Need for targeted therapeutic options in paediatric patients

Although the occurrence of TC is rare in children and adolescents, DTC in children and adolescents often follows a more aggressive clinical course when compared with adults. This could be attributed to the disparities observed in the molecular and clinicopathological characteristics observed between adolescent and adult TCs as well as the presence of more advanced disease at the time of diagnosis in children (Paulson et al. 2019).

For adult patients who have RAI-refractory DTC and have exhausted local treatment options, the next step of treatment is with systemic multi-targeted therapies, such as lenvatinib, sorafenib and cabozantinib. However, none of these systemic therapies is approved in paediatric patients less than 18 years of age. There is a need for additional treatment options, especially, targeted treatment agents.

## Extrapolation conclusion

In conclusion, based on the observed efficacy and safety in patients aged 12 years and above with RET fusion-positive TC from LIBRETTO-121, the available PK data, mechanism of action of selpercatinib and the high and similar unmet need in both adult and adolescent patients with TC, it is considered that the efficacy and safety data from LIBRETTO-001 in adult patients can be extrapolated to adolescent patients.

## 2.4.2. Discussion on clinical efficacy

The provided efficacy data in support of the currently intended indication 'treatment of adults and adolescents 12 years and older with advanced RET mutant thyroid cancer without prior standard first line therapy (i.e. first-line setting) is based on results from the ongoing study LOXO-RET-17001 (LIBRETTO-001) as of the cut-off date (DCO) of 21 June 2021 which was updated during the procedure with DCO 13 January 2023. This is an open-label, multicentre, phase 1/2 study which consisted of a dose escalation phase (phase 1) to determine the MTD and RP2D of selpercatinib followed by a Phase 2 expansion with diverse RET-altered cancer cohorts (6 cohorts), among them Thyroid Cancer in first line (cohort 2), and other tumours.

The Phase 1 portion of the study has been completed. The Phase 2 portion is ongoing.

## Design and conduct of clinical studies

LIBRETTO-001 is non-randomized and non-blinded single arm study. The absence of a control arm is an important limitation and a source of bias for a confirmatory study.

Overall, inclusion and exclusion criteria are considered acceptable.

In agreement with the PIP, Selection criteria allowed to include patients between 12 and 18 years old of age (in 4 countries) but no paediatric patients were enrolled in the study.

The primary endpoint, objective response rate (ORR) based on Independent Review Committee (IRC) assessment using RECIST v1.1, is acceptable. The secondary endpoints (i.e. ORR based on Investigator assessment, TTR, TTBR, DoR, CBR, PFS and OS) are relevant.

<div style=\"page-break-after: always\"></div>

Regarding the statistical analysis plan, while a sample size has been well defined for the whole Cohort 2, no minimum recruitment has been defined specifically for the TC subset. This represents a limitation to the interpretation of the results of the study.

Overall, the SAP is acceptable.

## Efficacy data and additional analyses

Overall, 921 patients were screened and 796 were enrolled in the pivotal Study LIBRETTO-001. Of these 786, 54 had a RET Fusion-Positive Thyroid Cancer (TC). Among them, 46 were included in the Efficacy Analysis Set, 16 patients in the TC:TrtSysNaïve population (without previous systemic treatment) and 30 in the TC:TrtSys (with previous systemic treatment).

Overall, the TC:TrtSysNaïve population remains very limited (i.e. 16) and while it is understood that RET Fusion-Positive TC is not common, it is however only the half of the TC:TrtSys population. Data from 8 additional patients with RET Fusion-Positive TC without prior systemic treatment have been provided during the assessment with a cut-off date 13 January 2023 bringing the TC:TrtSysNaïve population to 24 patients.

The demographics appears consistent with the condition. The median age was 60.5 years (range: 20 to 84 years), 58.3% of all patients were male. Additionally, the demographics does not present dramatics differences with the TC:TrtSys (with previous systemic treatment) population included in LIBRETTO-001.

The most represented histology TC subtype was papillary TC followed (n=15), and only 1 patient had a poorly differentiated TC which is consistent with the epidemiology of the disease. Patients were in a relatively good condition with 56.3% (n=9) of the patients with an ECOG of 0 and 37.5% (n=6) with an ECOG of 1, and only 1 patient with an ECOG of 2. Additionally, 93.8% (n=15) had a Stage IV disease (IV or IVB or IVC), and 100% (n=16) had a metastatic disease, which is in line with claimed indication (i.e.  advance or metastatic cancer).  No patients had received previous systemic therapy other than radioactive iodine.

The ORR at the first DCO was 93.8% (95%CI: 69.8, 99.8) as assessed by the IRC and was consistent with the ORR as assessed by Investigators 81.3% (95%CI: 54.4, 96.0). This level of response is seen as promising. Additionally, while the CI interval is broad, the low boundaries remain at a reasonable level of effect. Moreover, these results are consistent with those observed in second line setting (i.e. ORR assessed by IRC: 80.0% (95%CI: 61.4, 92.3).

According to the IRC, at the data cut-off of 21 June 2021, 31.3% (n=5) of the patients had a CR, 62.5% (n=10) a PR, and 6.3% (n=1) SD16+, for a clinical benefit rate of 100% (95%CI: 79.4, 100.0).

At that data cutoff, the data was too immature to provide the estimated median of the DoR, the PFS and the OS. It is nonetheless observed at a median follow-up of 20.1 months (95%CI: 9.3, 25.8), the rate of progression-free survival was 92.9% (95%CI: 59.1, 99.0) and at 24 months was 83.6% (95%CI: 48.0, 95.7).

The TTR and the TTBR assessed by IRC was respectively 1.8 months (25 th -75 th : 1.8, 4.6), and 3.6 months (25 th -75 th : 1.8, 5.5).

With the update data, ORR in a total of 24 patients was 95.8% (95%CI: 78.9, 99.9), 20.8 %(n=5) of the patients had a CR, and 75% (n=18) had PR. With a median duration of follow-up of 17.8 months the DoR is not reached.

Overall, the subgroups analysis, including by RET fusion partners genes, did not reveal any remarkable difference to main analysis.

<div style=\"page-break-after: always\"></div>

## Assessment of paediatric data on clinical efficacy

While,  for  Study  LIBRETTO-001  recruitment  was  open  for  adolescent  (in  agreement  with  the  PIP P/0133/2023),  no  patients  with RET fusion-positive  TC  aged  18  years  or  less  were  identified  for participation in the study. Considering the rarity of the conditions this can be understandable.

In absence of paediatric data in LIBRETTO-001, extrapolation of adult data to adolescents was proposed by the MAH. Extrapolation was justified based on the fact that the therapeutic benefit of a selective RET inhibitor  would  be  independent  of  age  and  the  clinical  outcomes  for  adolescent  patients  could  be extrapolated from clinical trials with predominant enrolment of adult patients as the clinical outcomes are primarily related to the molecular basis of cancer, their associated pathways and PK responses. Moreover  the  medications  designed  for  some  cancers  in  adults  may  affect  the  same  pathways  in childhood and adolescent cancers.

These hypotheses were however poorly justified and documented and the arguments provided to justify the extrapolation of the results in adults to the paediatric population were not considered satisfactory.

As of today, there is a lack of age-specific treatment international guidelines.  Based on American Thyroid Association (ATA) published paediatric specific treatment guidelines for thyroid cancer (Francis et al. 2015), the primary differences for children and adolescents hinge around prevention of late effects by considering the appropriateness and timing of surgical resection and RAI administration the difference in frequency of molecularly driven thyroid cancers; genomically altered thyroid cancer is predominant in children.  This  is  acknowledged  and  suggests  a  similarity  in  the  treatment  strategy  across  the  two population. However, this is not a demonstration of the similarity of the disease.

To support an indication in adolescents, data from an ongoing Phase 1/2 paediatric study LIBRETTO-121 were submitted. In this trial overall 31 patients were screened and 27 were enrolled (4 screen failure). Of these, 10 had a RET Fusion-Positive TC and were included in the efficacy analysis. Eight patients were aged 12 to 17 years and 2 were aged 18 to 20 years.

ORR was 60.0% (95%CI: 26.2, 87.8) as assessed by the IRC. Three patients had confirmed complete response whilst 3 patients had confirmed partial response. This was consistent with the ORR as assessed by Investigators 50.0% (95%CI: 18.7, 81.3). Although, this level of response can be seen as promising, it appears lower compared to adults. It is acknowledged that 70% of the patients were in 2n+ lines, however the OR remain lower than for adults previously treated with systemic therapy (85.4% (95%CI: 70.8, 94.4)). Three (42.9%) patients with non-measurable disease were included in the study LIBRETTO-121 while none were included in LIBRETTO-001 and patients with non-measurable disease can be considered responders only if they have CR and otherwise must be considered to have non-CR/non-PR or PD. Additionally, paediatric patients with measurable disease (n=4, 57,1%) had an ORR of 100%. Even though uncertainties remained on the effect size, the ORR data in the paediatric population are promising.

## Additional efficacy data needed in the context of a conditional MA

The main limitations in relation to the efficacy of selpercatinib are related to the uncontrolled nature of the pivotal evidence which hampers the assessment of the time-to-event endpoints and the limited number of patients included.

To confirm the benefits observed in study LIBRETTO-001 for the adult's patient population and in order to fulfil a CMA the MAH will submit the final data from the cohort 2 of the pivotal study LIBRETTO-001 (Dec 2025).

<div style=\"page-break-after: always\"></div>

Data from LIBRETTO-121 are considered immature. In order to confirm the benefits observed in the adolescent patients population 12 year and older and fulfil the CMA criteria, the MAH will submit longterm data from the study LIBRETTO-121 (June 2025).

## 2.4.3. Conclusions on the clinical efficacy

The efficacy results from the ongoing phase 1/2 study LIBRETTO-001 in patients with systemic treatment naïve  RET  fusion-positive  thyroid  cancer  and  the  efficacy  result  from  Phase  1/2  paediatric  study, LIBRETTO-121 can be considered clinically meaningful. Although immature, estimates for the secondary endpoint are also promising.

Since efficacy results are still immature, data corresponding to a longer follow-up are required (the SOBs studies related to the CMA).

The CHMP considers the following measures necessary to address the missing efficacy data in the context of a conditional MA:

- -In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with systemic treatment naïve RET fusion-positive thyroid cancer, the MAH should submit the final data from the cohort 2 of the pivotal study LIBRETTO-001 by December 2025
- -In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with RET fusion-positive thyroid cancer, the MAH should submit the final data from the study LIBRETTO-121 by June 2025

## 2.5. Clinical safety

## Introduction

Safety data available from a total of 796 patients in the LIBRETTO 001 study which is still ongoing were submitted at the start of the procedure and are presented below.  An updated safety data set with a total of 837 patients was submitted and assessed in the context of the annual renewal of Retsevmo (EMEA/H/C/005375/R/0026).

Of the 796 patients, 54 (~ 7%) had RET fusion-positive TC and includes 18 (~34%) who were not previously treated with systemic therapy other than Radioactive iodine (RAI; TC: TrtSysNaïve). All patients in the ITT population received at least one dose of selpercatinib as of the data cut-off date of 15 June 2021.

<div style=\"page-break-after: always\"></div>

Table 31. Description of Safety Analysis Sets (data Cut-off: 15 June 2021)

| Set Name                  | Safety Analysis Set                | Analysis Set Description                                                                                                                                                                                                                                                           | Number of Patients   |
|---------------------------|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Overall Safety Population | Overall Safety Analysis Set (OSAS) | All patients who received at least 1 or more doses of selpercatinib regardless of diagnosis or line of therapy.                                                                                                                                                                    | N=796                |
| TC Safety Population      | TC Safety Analysis Set             | All patients with RET fusion-positive TC who received at least 1 dose of selpercatinib. This is a subset of the Overall Safety Population.                                                                                                                                         | N=54                 |
| TC:TrtSysNaive (Safety)   | TC:TrtSysNaive Safety Analysis Set | All patients with RET fusion-positive TC that have had no prior systemic therapy (lenvatinib, sorafenib) and/or other systemic therapy other than RAI, met the criteria in footnote a, and received at least 1 dose of selpercatinib.This is a subset of the TC Safety Population. | N=18                 |
| TC:TrtSys (Safety)        | TC:TrtSys Safety Analysis Set      | All patients with RET fusion-positive TC previously treated with systemic therapy (lenvatinib, sorafenib), or other systemic therapy, met the criteria in footnote a, and received at least 1 dose of selpercatinib. This is a subset of the TC Safety Population.                 | N=36                 |

Abbreviations: N = number of subjects in the analysis population; RAI = radioactive iodine; RET = REarranged during Transfection; TC = thyroid cancer; TC:TrtSys = Patients Previously Treated with Systemic Therapy in the safety analysis set; TC:TrtSysNaive = Patients Not Previously Treated with Systemic Therapy other than RAI in the safety analysis set.

## Patient exposure

Through 15 June 2021, a total of 796 patients have been treated with selpercatinib at doses ranging from 20 mg QD to 240 mg BID, most patients (96% ) received at least 1 dose of the selpercatinib recommended dose (Phase 2 dose) of 160 mg BID.

Five hundred thirty-nine (539) patients (68%) were still on study, of which 462 patients (58%, including 39 patients with TC) were still receiving selpercatinib and 77 patients (10%, including 3 patients with TC) were in follow-up, but off treatment. No adolescent patients are present from the ongoing pivotal study LIBRETTO-001 in the advanced RET fusion-positive TC population.

The most common reason for treatment discontinuation in the Overall Safety Population was disease progression (23%), followed by AE (~8%).

The most common reason for treatment discontinuation in the TC Safety Population was disease progression (13%), followed by withdrawal of consent (5.6%), significant non-compliance to protocol (3.7%) and AE (1.9%).

In the TC Safety Population, 94.4% patients received at least 1 dose of selpercatinib 160 mg BID and 94.4% patients had a selpercatinib starting dose of 160 mg.

<div style=\"page-break-after: always\"></div>

Table 32. Treatment and study disposition (TC Safety Population)

| Status                                                 | Treated (N= 36)   | Naive (N= 18)   | Total Thyroid (N= 54)   |
|--------------------------------------------------------|-------------------|-----------------|-------------------------|
| Treatment Status (n,&)                                 |                   |                 |                         |
| Discontinued                                           | 12(33.3)          | 3(16.7)         | 15  (27.8)              |
| Continuing                                             | 24(66.7)          | 15(83.3)        | 39(72.2)                |
| Reason Treatment Discontinued (n,&)                    |                   |                 |                         |
| Progressive Disease                                    | LD (16.7)         | 5.6)            | 13.0)                   |
| Adverse Event                                          | 1 2.8)            | 0 0.0)          | 1.9)                    |
| Requirement for Alternative Treatment per Investigator | 1 2.8)            | 0 0.0)          | 1.9)                    |
| Significant Noncompliance to Protocol                  | 2 5.6)            | 0 0.0)          | 2 3.7)                  |
| Withdrawal of Consent                                  | 2 5.6)            | 1 5.6)          | 3 5.6)                  |
| Other                                                  | 0 0.0)            | 1 5.6)          | 1.9)                    |
| Study Status (n,&)                                     |                   |                 |                         |
| Discontinued                                           | 10 (27.8)         | 2 ( 11.1)       | 12 ( 22.2)              |
| Continuing                                             | 26 ( 72.2)        | 16 ( 88.9)      | 42 ( 77.8)              |
| Reason Study Discontinued （n,)                         |                   |                 |                         |
| Withdrawal of Consent                                  | 2 5.6)            | 5.6)            | 3 5.6)                  |
| Death                                                  | 7 (19.4)          | 1 5.6)          | 8 14.8)                 |
| Other                                                  | 1 2.8)            | 0 0.0)          | 1 1.9)                  |

The median time on treatment was 21.3, 20.2 and 22.65 months, respectively, for the Overall Safety Population, overall TC Safety Population and naïve TC population.

The most reported dose modification was dose withheld (72.9% in the Overall Safety Population and 63% in the TC Safety Population) primarily attributed to adverse events (AEs) (64.1% in the Overall Safety Population and 55.6% in the overall TC Safety Population).

## Adverse events

A summary of all-causality and treatment-related AEs registered across data-cut-off dates is shown in below table.

Table 33. Treatment-Emergent Adverse Events across Data Cut-Off Dates

|                                        | TC:IrtSysNaive (Safety) Patients   | TCSafetyPopulation   | TCSafetyPopulation   | TCSafetyPopulation   | OverallSafetyPopulation   | OverallSafetyPopulation   | OverallSafetyPopulation   |
|----------------------------------------|------------------------------------|----------------------|----------------------|----------------------|---------------------------|---------------------------|---------------------------|
| Data cut-off date                      | 15 Jum 2021 N=18                   | 16 Dec 2019 N=37     | 30Mar2020 N = 42     | 15 Jum 2021 N=54     | 16 Dec 2019 N=702         | 30Mar2020 N = 746         | 15 Jum 2021 N=796         |
| Any TEAEs, n (%)                       | 18 (100.0)                         | 37 (100.0)           | 42 (100.0)           | 54 (100.0)           | 695 (99.0)                | 740 (99.2)                | 795 (99.9)                |
| Related to selpercatinib               | 18 (100.0)                         | 34 (91.9)            | 41 (97.6)            | 53 (98.1)            | 640 (91.2)                | 690 (92.5)                | 756 (95.0)                |
| Grade≥3TEAEs.n(%)                      | 10 (55.6)                          | 23 (62.2)            | 25 (59.5)            | 37 (68.5)            | 415 (59.1)                | 445 (59.7)                | 572 (71.9)                |
| Related to selpercatinib               | 8 (44.4)                           | 12 (32.4)            | 13 (31.0)            | 17 (31.5)            | 206 (29.3)                | 239 (32.0)                | 307 (38.6)                |
| TESAEs, n (%)                          | 4 (22.2)                           | 13 (35.1)            | 14 (33.3)            | 20 (37.0)            | 234 (33.3)                | 262 (35.1)                | 353 (44.3)                |
| Related to selpercatinib               | 2 (11.1)                           | 1 (2.7)              | 1 (2.4)              | 3 (5.6)              | 54 (7.7)                  | 62 (8.3)                  | 87 (10.9)                 |
| TEAEs leading to discontinuation,an(%) | 0 (0.0)                            | 2 (5.4)              | 2 (4.8)              | 2 (3.7)              | 37 (5.3)                  | 45 (6.0)                  | 64 (8.0)                  |
| Related to selpercatinib               | 0 (0.0)                            | 0 (0.0)              | 0 (0.0)              | 0 (0.0)              | 14 (2.0)                  | 16 (2.1)                  | 25 (3.1)                  |
| Fatal TEAEs, n (%)                     | 0 (0.0)                            | 1 (2.7)              | 1 (2.4)              | 1 (1.9)              | 21 (3.0)                  | 25 (3.4)                  | 45 (5.7)                  |
| Related to selpercatinib               | 0 (0.0)                            | 0 (0.0)              | 0 (0.0)              | 0 (0.0)              | 0                         | 0 (0.0)                   | 1 (0.1)                   |

Abbreviations:CTCAE=CommonTerminology Criteria forAdverseEvents;n=number ofpatients in specific category;N=number of subjects in the analysis population; RAI = radioactive iodine; TC = thyroid cancer; TC:TrtSysNaive (Safety) = patients not previously treated with systemic therapy other than RAI in the safety analysis set; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious adverse event.

Permanentlydiscontinued.

<div style=\"page-break-after: always\"></div>

Table 34. Summary of Treatment-Emergent Adverse overall Safety Population and TC Safety Population

| Analysis Set                            | TC:TrtSysNaive (Safety) N=18   | TC:IrtSys (Safety) N=36   | TC Safety Population N=54   | Overall Safety Population N = 796   |
|-----------------------------------------|--------------------------------|---------------------------|-----------------------------|-------------------------------------|
| Data cut-off date                       | 15 Jum 2021                    | 15 Jum 2021               | 15 Jum 2021                 | 15 Jum 2021                         |
| Any TEAEs, n (%)                        | 18 (100.0)                     | 36 (100.0)                | 54 (100.0)                  | 795 (99.9)                          |
| Related toselpercatinib                 | 18 (100.0)                     | 35 (97.2)                 | 53 (98.1)                   | 756 (95.0)                          |
| Grade ≥3 TEAEs. n (%)                   | 10 (55.6)                      | 27 (75.0)                 | 37 (68.5)                   | 572 (71.9)                          |
| Relatedtoselpercatinib                  | 8 (44.4)                       | 9 (25.0)                  | 17 (31.5)                   | 307 (38.6)                          |
| TESAEs, n (%)                           | 4 (22.2)                       | 16 (44.4)                 | 20 (37.0)                   | 353 (44.3)                          |
| Related to selpercatinib                | 2 (11.1)                       | 1 (2.8)                   | 3 (5.6)                     | 87 (10.9)                           |
| TEAEs leading to discontinuation, n (%) | 0 (0.0)                        | 2 (5.6)                   | 2 (3.7)                     | 64 (8.0)                            |
| Related to selpercatinib                | 0 (0.0)                        | 0 (0.0)                   | 0 (0.0)                     | 25 (3.1)                            |
| Fatal TEAEs, n (%)                      | 0 (0.0)                        | 1 (2.8)                   | 1 (1.9)                     | 45 (5.7)                            |
| Related toselpercatinib                 | 0 (0.0)                        | 0 (0.0)                   | 0 (0.0)                     | 1 (0.1)                             |

Abbreviations: N = number of patients in the analysis population; n = number of patients in the specific category; TC = thyroid cancer; TC:IrtSysNaive (Safety) = patients not previously treated with systemic therapy other than RAI in the safety analysis set; IC:TrtSys (Safety) = patients previously treated with systemic therapy in the safety analysis set; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious adverse event.

<div style=\"page-break-after: always\"></div>

Table 35. Treatment-Emergent Adverse Events by Decreasing Frequency Any Grade in ≥15% of TC Safety Population Patients Overall Safety Population and TC Safety Population

Table 36. Treatment-Emergent Adverse Events Grade ≥3 occurring in ≥2% of Overall Safety Population and TC Safety Population Data Cut-off: 15 June 2021

|                            | TC Safety Population N= 54   | TC Safety Population N= 54   | Overall Safety Population N=796   | Overall Safety Population N=796   |
|----------------------------|------------------------------|------------------------------|-----------------------------------|-----------------------------------|
| Preferred or CompositeTerm | Any Grade n (%)              | Grade ≥3 n (%)               | Any Grade n (%)                   | Grade ≥3 n (%)                    |
| Patients with ≥l TEAE      | 54 (100.0)                   | 37 (68.5)                    | 795 (99.9)                        | 572 (71.9)                        |
| Oedema                     | 14 (25.9)                    | 0 (0.0)                      | 386 (48.5)                        | 6 (0.8)                           |
| Diarrhoea                  | 22 (40.7)                    | 3 (5.6)                      | 370 (46.5)                        | 40 (5.0)                          |
| Dry mouth                  | 25 (46.3)                    | 0 (0.0)                      | 344 (43.2)                        | 0 (0.0)                           |
| Hypertension               | 21 (38.9)                    | 9 (16.7)                     | 319 (40.1)                        | 155 (19.5)                        |
| Fatigue                    | 25 (46.3)                    | 1 (1.9)                      | 303 (38.1)                        | 18 (2.3)                          |
| AST increased              | 10 (18.5)                    | 3 (5.6)                      | 292 (36.7)                        | 70 (8.8)                          |
| ALT increased              | 11 (20.4)                    | 3 (5.6)                      | 284 (35.7)                        | 91 (11.4)                         |
| Constipation               | 20 (37.0)                    | 0 (0.0)                      | 261 (32.8)                        | 6 (0.8)                           |
| Nausea                     | 14 (25.9)                    | 0 (0.0)                      | 248 (31.2)                        | 9 (1.1)                           |
| Headache                   | 12 (22.2)                    | 0 (0.0)                      | 219 (27.5)                        | 11 (1.4)                          |
| Abdominal pain             | 17 (31.5)                    | 3 (5.6)                      | 205 (25.8)                        | 20 (2.5)                          |
| Blood creatinine increased | 10 (18.5)                    | 0 (0.0)                      | 204 (25.6)                        | 6 (0.8)                           |
| Vomiting                   | 14 (25.9)                    | 2 (3.7)                      | 178 (22.4)                        | 14 (1.8)                          |
| Rash                       | 14 (25.9)                    | 0 (0.0)                      | 173 (21.7)                        | 3 (0.4)                           |
| ECG QT prolongation        | 9 (16.7)                     | 3 (5.6)                      | 165 (20.7)                        | 38 (4.8)                          |
| Arthralgia                 | 13 (24.1)                    | 1 (1.9)                      | 165 (20.7)                        | 2 (0.3)                           |
| Back pain                  | 13 (24.1)                    | 1 (1.9)                      | 153 (19.2)                        | 12 (1.5)                          |
| Cough                      | 10 (18.5)                    | 0 (0.0)                      | 153 (19.2)                        | 0 (0.0)                           |
| Decreased appetite         | 11 (20.4)                    | 0 (0.0)                      | 150 (18.8)                        | 3 (0.4)                           |
| Dyspnoea                   | 8 (14.8)                     | 2 (3.7)                      | 150 (18.8)                        | 25 (3.1)                          |
| Pyrexia                    | 12 (22.2)                    | 0 (0.0)                      | 135 (17.0)                        | 1 (0.1)                           |
| Dry skin                   | 10 (18.5)                    | 0 (0.0)                      | 122 (15.3)                        | 0 (0.0)                           |
| Hypocalcaemia              | 13 (24.1)                    | 1 (1.9)                      | 121 (15.2)                        | 22 (2.8)                          |
| Lymphopenia                | 11 (20.4)                    | 4 (7.4)                      | 111 (13.9)                        | 41 (5.2)                          |

<div style=\"page-break-after: always\"></div>

|                                     | TC Safety Population N=54   | Overall SafetyPopulation N =796   |
|-------------------------------------|-----------------------------|-----------------------------------|
| Preferred or Composite Term         | Grade ≥3 n (%)              | Grade ≥3 n (%)                    |
| Patients with TEAEs                 | 37 (68.5)                   | 572 (71.9)                        |
| Hypertension                        | 9 (16.7)                    | 155 (19.5)                        |
| Alanineaminotransferase increased   | 3 (5.6)                     | 91 (11.4)                         |
| Aspartateaminotransferase increased | 3 (5.6)                     | 70 (8.8)                          |
| Hyponatraemia                       | 4 (7.4)                     | 64 (8.0)                          |
| Lymphopenia                         | 4 (7.4)                     | 41 (5.2)                          |
| Diarrhoea                           | 3 (5.6)                     | 40 (5.0)                          |
| ECG QTprolongation                  | 3 (5.6)                     | 38 (4.8)                          |
| Pneumonia                           | 2 (3.7)                     | 34 (4.3)                          |
| Dyspnoea                            | 2 (3.7)                     | 25 (3.1)                          |
| Thrombocytopenia                    | 2 (3.7)                     | 24 (3.0)                          |
| Anaemia                             | 3 (5.6)                     | 23 (2.9)                          |
| Hypocalcaemia                       | 1 (1.9)                     | 22 (2.8)                          |
| Pleural effusion                    | 1 (1.9)                     | 21 (2.6)                          |
| Abdominal pain                      | 3 (5.6)                     | 20 (2.5)                          |
| Hypophosphataemia                   | 3 (5.6)                     | 20 (2.5)                          |
| Neutropenia                         | 2 (3.7)                     | 20 (2.5)                          |
| Fatigue                             | 1 (1.9)                     | 18 (2.3)                          |
| Hyperkalaemia                       | 2 (3.7)                     | 16 (2.0)                          |
| Sepsis                              | 2 (3.7)                     | 15 (1.9)                          |
| Hyperglycaemia                      | 1 (1.9)                     | 13 (1.6)                          |
| Back pain                           | 1 (1.9)                     | 12 (1.5)                          |
| Embolism                            | 2 (3.7)                     | 6 (0.8)                           |

Abbreviations: ECG = electrocardiogram; N = number of patients; n = number of patients in the specific category; PT = preferred term; TEAE = treatment-emergent adverse event; TC = thyroid cancer. Notes: The component PTs comprising each composite term are in italics in the Table 8.32. Adverse events are sorted in descending frequency based on the overall count in the Overall Safety Population. Data cutoff date: 15 June 2021.

The most frequent TEAEs (any grade) occurring in 30% or more in the Overall Safety Population were oedema, diarrhoea, fatigue, dry mouth, hypertension, AST increased, ALT increased, constipation, rash abdominal pain  and nausea .

The most frequent TEAEs (any grade) occurring 30% or more in the TC Safety Population were dry mouth, fatigue, diarrhoea, hypertension, constipation, abdominal pain.

The most frequent TEAEs (any grade) occurring 30% or more in the TC: TrtSysNaïve (Safety) were abdominal pain, rash, headache, and lymphopaenia.

The most common Grade ≥ 3 TEAEs in both the Overall and TC Safety Populations were hypertension followed by ALT increased and AST increased. There were no Grade 5 (fatal) events noted for these 3 TEAEs in either of the populations.

The most frequent Grade 3 or higher TEAEs reported in 5% or more of patients in both the TC: TrtSysNaïve (Safety) patients and Overall Safety Population were hypertension, lymphopaenia hyponatraemia, ALT increased, AST increased, and diarrhoea. There were no Grade 5 (fatal) events noted for these 6 TEAEs in either of the populations.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious AEs

The most common serious TEAEs observed in both the Overall Safety Population and TC safety population are shown in table below.

Table 37 The most common serious TEAEs observed in both the Overall Safety Population and TC safety population

|                                       | TC SafetyPopulation N=54   | TC SafetyPopulation N=54   | Overall SafetyPopulation N = 796   | Overall SafetyPopulation N = 796   |
|---------------------------------------|----------------------------|----------------------------|------------------------------------|------------------------------------|
| Preferred Term                        | All Causality n (%)        | Related n (%)              | All Causality n (%)                | Related n (%)                      |
| Patients with treatment-emergent SAEs | 20 (37.0)                  | 3 (5.6)                    | 353 (44.3)                         | 87 (10.9)                          |
| Pneumonia                             | 2 (3.7)                    | 0 (0.0)                    | 33 (4.1)                           | 0 (0.0)                            |
| Abdominal pain                        | 3 (5.6)                    | 1 (1.9)                    | 18 (2.3)                           | 3 (0.4)                            |
| Dyspnoea                              | 1 (1.9)                    | 0 (0.0)                    | 18 (2.3)                           | 0 (0.0)                            |
| Hyponatraemia                         | 1 (1.9)                    | 0 (0.0)                    | 18 (2.3)                           | 0 (0.0)                            |
| Diarrhoea                             | 1 (1.9)                    | 0 (0.0)                    | 15 (1.9)                           | 3 (0.4)                            |
| Sepsis                                | 2 (3.7)                    | 0 (0.0)                    | 13 (1.6)                           | 0 (0.0)                            |
| Alanine aminotransferase increased    | 1 (1.9)                    | 0 (0.0)                    | 12 (1.5)                           | 9 (1.1)                            |
| Aspartate aminotransferase increased  | 1 (1.9)                    | 0 (0.0)                    | 12 (1.5)                           | 9 (1.1)                            |
| Acute respiratory failure             | 1 (1.9)                    | 0 (0.0)                    | 11 (1.4)                           | 1 (0.1)                            |
| Vomiting                              | 2 (3.7)                    | 1 (1.9)                    | 11 (1.4)                           | 1 (0.1)                            |
| Pyrexia                               | 2 (3.7)                    | 0 (0.0)                    | 10 (1.3)                           | 2 (0.3)                            |
| Dehydration                           | 1 (1.9)                    | 0 (0.0)                    | 9 (1.1)                            | 3 (0.4)                            |

Abbreviations: N = number of patients; n = number of patients in the specific category; SAE = serious adverse event; TC = thyroid cancer.

The most common treatment-emergent serious adverse events (TE-SAEs) occurring in ≥2% of patients in the TC Safety Populations were abdominal pain, pneumonia, sepsis, vomiting and pyrexia.

The most common treatment-emergent serious adverse events (TE-SAEs) occurring in ≥2% of patients in the TC: TrtSysNaïve Population were abdominal pain, sepsis, respiratory failure, vomiting, cardiac failure, diverticulitis, cholestasis, hepatic haemorrhage, and lymphopaenia.

The most common treatment-emergent serious adverse events (TE-SAEs) occurring in ≥2% of patients in both the Overall and TC Safety Populations were pneumonia, abdominal pain.

## Deaths

<div style=\"page-break-after: always\"></div>

Table 38. Summary of Deaths Overall Safety Population and TC Safety Population

|                                              | TC Safety Population N = 54   | Overall Safety Population N= 796   |
|----------------------------------------------|-------------------------------|------------------------------------|
| Within 28 days of the last dose, n (%)       | 1 (1.9)                       | 56 (7.0)                           |
| Disease progression                          | 1 (1.9)                       | 19 (2.4)                           |
| Adverse event                                | 0 (0.0)                       | 34 (4.3)                           |
| Other                                        | 0 (0.0)                       | 3 (0.4)a                           |
| More than 28 days after the last dose, n (%) | 7 (13.0)                      | 137 (17.2)                         |
| Disease progression                          | 5 (9.3)                       | 109 (13.7)                         |
| Adverse event                                | 1 (1.9)                       | 10 (1.3)                           |
| Other                                        | 1 (1.9)b                      | 18 (2.3)                           |

Abbreviations: N = number of patients; n = number of patients in the specific category; TC = thyroid cancer.

Note: Percentage is calculated based on the number of patients in the column heading as the denominator.

a Other included: disease progression, with additional symptoms, reported as \"other\".

Data cutoff date: 15 June 2021.

b  Other included: (1) bone metastasis.

## Adverse Events of Special Interest

## AST/ALT increased

AST and ALT increases were reported in 36.7% and 35.7% of patients in the Overall Safety Population and 18.5% and 20.4% of patients in the TC Safety Population, respectively. Majority were of Grade 1 or 2.

## Hypertension

The incidence of any-grade hypertension was reported in similar proportion in both the Overall Safety Population (41%) and TC safety population (40.7%), 19.7% and 16.7% were Grade ≥ 3 in the Overall and TC Safety Population, respectively. Patients with a documented history of hypertension displayed a higher incidence of treatment-emergent Grade 3 hypertension than patients without (28% versus 14%, respectively). This trend is the same in the TC safety population (28.6% versus 3.8, respectively).

## Hypersensitivity

The overall incidence of any-grade hypersensitivity was 5.9% in the Overall Safety Population. A total of 15 patients (1.9%) in the Overall Safety and none patients in the TC Safety Population had Grade 3 hypersensitivity.

## QT prolongation

Electrocardiogram QT prolonged was reported as a TEAE in similar proportion of the patients in both the Overall (21.1%) and TC (16.7%) Safety Populations. Most patients had TEAEs of Grade 1 or 2 in severity in both the Overall Safety (16.3%) and TC safety (11.2%) population.

## Laboratory findings

The highest incidence of any grade treatment-emergent laboratory abnormality across haematology parameters was reported for decreased lymphocyte count (51.8% and 57.7%) and decreased white blood cell count (48.7% and 44.2%) in both the Overall Safety Population and the TC Safety Population, respectively.

<div style=\"page-break-after: always\"></div>

The highest incidence of any grade treatment-emergent serum abnormality was reported for calcium decreased (58.7 and 59.6 %), and albumin decreased (55.7% and 57.7%) in both the Overall Safety Population and the TC Safety Population, respectively.

## Safety in special populations

There were no significant differences in the incidence of TEAEs among the age, sex, and race subgroups in the Overall Safety and TC Safety Populations.

## Safety related to drug-drug interactions and other interactions

Please refer to the PK part.

## Discontinuation due to adverse events

The most frequently reported TEAEs leading to doses being withheld in 5% or more patients in both the Overall Safety Population and Treatment-Naïve Patients were ALT increase, AST increased and diarrhoea.

The most frequently reported TEAEs leading to a dose reduction in 5% or more patients in both the Overall Safety Population and the TC: TrtSysNaïve Population (safety) were AST increase and diarrhoea.

The most frequently reported TEAEs leading to permanent discontinuation of selpercatinib in 4 or more patients in the Overall Safety Population were ALT increased, fatigue, AST increase, and sepsis. All other AEs occurred in less than 4 patients. In the TC: TrtSysNaïve Population (safety) no events leading to permanent discontinuation of selpercatinib were reported.

## Safety in paediatric patient population

The safety data for the paediatric patient population derived from Study LIBRETTO-121. As of 13 January 2023, a total of 8 patients with RET fusion-positive TC aged 12 to 17 years and 2 patients aged 18 to 21 years have enrolled into the Study.

Table 39 shows the overall safety profile and Table 40 shows TEAEs experienced in the 8 adolescent patients with RET fusion-positive TC.

Table 39. Overall Safety RET Fusion-Positive TC Study LIBRETTO-121

Data Cutoff Date

N

n (%)

PTC

12 to 21 Years

(N =10)

10

PTC

12 to 17 Years

(N = 8)

8

| Patients with TEAEs                                                | 10 (100.0)   | 8 (100.0)   |
|--------------------------------------------------------------------|--------------|-------------|
| PatientswithTEAEsrelated to selpercatinib                          | 9 (90.0)     | 7 (87.5)    |
| PatientswithTEAEsGrade3or above                                    | 4 (40.0)     | 3 (37.5)    |
| Patients with TEAEs Grade 3 or above and related to selpercatinib  | 2 (20.0)     | 2 (25.0)    |
| Patientswithpermanentdiscontinuation of selpercatinib due to TEAEs | 0 (0.0)      | 0 (0.0)     |
| Patients with serious TEAEs                                        | 0 (0.0)      | 0 (0.0)     |

Abbreviations: n = number of patients in the specified category; N = number of patients; PTC = papillary thyroid cancer; RET = REarranged during Transfection; TC = thyroid cancer; TEAE = treatment-emergent adverse events.

13January 2023

<div style=\"page-break-after: always\"></div>

Table 40. Treatment-Emergent Adverse Events Experienced by 2 or More Patients by Preferred Term (RET Fusion-Positive Thyroid Cancer Population) Study LIBRETTO-121 Safety Analysis Set

| Data Cutoff Date           | 13 January 2023            | 13 January 2023           |
|----------------------------|----------------------------|---------------------------|
| N                          | PTC 12 to 21 Years (N =10) | PTC 12 to 17 Years (N =8) |
| Preferred Term (n %)       |                            |                           |
| Diarrhoea                  | 6 (60.0)                   | 4 (50.0)                  |
| Corona virus infection     | 4 (40.0)                   | 4 (50.0)                  |
| Oropharyngeal pain         | 4 (40.0)                   | 4 (50.0)                  |
| AST increase               | 4 (40.0)                   | 4 (50.0)                  |
| Cough                      | 4 (40.0)                   | 3 (37.5)                  |
| ALT increase               | 3 (30.0)                   | 3 (37.5)                  |
| Blood creatinine increased | 3 (30.0)                   | 3 (37.5)                  |
| Headache                   | 2 (20.0)                   | 2 (25.0)                  |
| Nausea                     | 2 (20.0)                   | 2 (25.0)                  |
| Pyrexia                    | 2 (20.0)                   | 2 (25.0)                  |
| Abdominal pain             | 3 (30.0)                   | 2 (25.0)                  |
| Blood bilirubinincreased   | 3 (30.0)                   | 2 (25.0)                  |
| Fatigue                    | 2 (20.0)                   | 2 (25.0)                  |
| Asthenia                   | 2 (20.0)                   | 2 (25.0)                  |
| Dizziness                  | 2 (20.0)                   | 2 (25.0)                  |
| Neutrophilcountdecrease    | 2 (20.0)                   | 2 (25.0)                  |
| Dysmenhorrhea              | 2 (20.0)                   | 2 (25.0)                  |
| Eczema                     | 2 (20.0)                   | 1 (12.5)                  |

Abbreviations: AST = aspartate aminotransferase; n = number of patients in the specified category; N = number of patients; PTC = papillary thyroid cancer.

Grade 3 or more TEAEs occurred in 4 patients with RET fusion-positive TC and there

- were 2 events of neutrophil count decrease, Grade 3, assessed as related to selpercatinib by the investigator
- was 1 event of weight gain, Grade 3, assessed as not related to selpercatinib by the investigator
- was 1 event of creatine kinase increase, Grade 4, assessed as not related to selpercatinib by the investigator, and
- was 1 event of epistaxis, Grade 3, assessed as not related to selpercatinib by the investigator.

## Post marketing experience

As of April 2022, Selpercatinib was approved in 36 countries including those in the EU, the US and Switzerland for treatment of patients with RET fusion-positive NSCLC and RET-mutant medullary thyroid cancer  regardless  of  line  of  therapy,  and  RET  fusion-positive  TC  in  the  second-line  setting.  Specific patient  populations  and  dosing  guidance  vary  by  country.  Cumulatively,  up  to  30  April  2022,  an estimated 1900 patients were exposed to selpercatinib worldwide. The data reported from the postmarketing setting are generally consistent with the known safety profile of selpercatinib. Most events were  reported  as  non-serious,  and  the  most  frequently  reported  events  were  recognised  ADRs  for selpercatinib or clinically expected in the target indication.

Overall, no new significant safety information has been identified from post-marketing sources. The periodic safety update report/periodic benefit-risk evaluation report with a data lock of 08 May 2022 confirmed and supported the previously established favourable benefit-risk profile for selpercatinib in the currently approved indications.

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

Whitin this procedure safety was evaluated in patients from the Overall Safety Population (N=796) and in the TC Safety Population (N=54) who received at least 1 dose of selpercatinib as of the data cut-off date of 15 June 2021. The overall Safety Population included in the SmPC (837 patients) derives from Procedure EMEA/H/C/005375/R/0026 concluded on 05/01/2024.

No adolescent patients are present from the ongoing pivotal study LIBRETTO-001 in the advanced RET fusion-positive TC population.

In terms of exposure, the median time on treatment was 21.29 and 20.2 months, respectively, for the Overall Safety Population and TC Safety Population. In the Treatment-Naïve Patients (not previously treated with systemic therapy other than RAI - TC: TrtSysNaïve patients) (n=18), the median treatment duration is 22.3 months (range: 0.4 to 35.6 months) and 86.2% of patients were on treatment for at least 24 months.

The median relative dose intensity was similar for the Overall Safety Population (94.5%) and the TC Safety Population (96.9%).

The most reported dose modification was dose withheld (72.9% in the Overall Safety Population and 63.0% in the TC Safety Population) primarily attributed to adverse events (AEs) (64.2% in the Overall Safety Population and 57.4% in the TC Safety Population).

The types and incidence rates of AEs leading to doses being withheld, dose reductions, and treatment discontinuation were consistent between the Overall Safety Population and Treatment-Naïve Patients (not previously treated with systemic therapy other than RAI - TC:TrtSysNaïve patients).

The most frequent TEAEs reported in 2% or more patients both in the Overall Safety Population and TC: TrtSysNaïve (Safety) were pneumonia and abdominal pain.

Fatal TEAEs were reported in 21 patients at the initial MAA compared with 45 patients at the 15 June 2021 data cut-off. In Treatment-Naïve Patients, a fatal (Grade 5) TEAE was experienced by one patient late onset and due to disease progression.

The adverse events of special interest (AESIs) analysed did not change compared to those reported previously for Retsevmo.

The safety profile observed in the data from the 15 June 2021 cut-off and from the 13 January 2023 cut-off  (procedure  EMEA/H/C/005375/R/0026  concluded  on  05/01/2024)  concluded  on  05.01.2024). remains consistent with previously reported data. No new ADRs or AESIs have been identified since initial authorisation and the safety profile is consistent between the TC: TrtSysNaïve patients and the Overall Safety Population.

There  were  8  patients  &lt;  18  years  (range  12-17)  of  age  with  RET  fusion  positive  thyroid  cancer  in LIBRETTO 121. No unique safety findings in children aged less than 18 years have been identified.

The safety profile of the existing key risks of liver injury and cardiac arrhythmia due to QT prolongation were consistent with the previous analysis.

## Additional safety data needed in the context of a conditional MA

Although safety results remain consistent with previously reported data they come from a low number of  adult  and  paediatric  patients  with  TC:TrtSysNaïve.  Further  safety  data  will  be  provided  from LIBRETTO-001 and study LIBRETTO-121 as specific obligations (SOBs).

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on clinical safety

The overall safety profile of selpercatinib in the Patients with Thyroid Carcinomas Not Previously Treated with systemic therapy other than RAI is overall consistent with that of the Overall Safety Population. The safety data submitted as part of this application indicate a safety profile for selpercatinib consistent with that reported previously.. Longer-term safety data from adult and paediatric patient with TC:TrtSysNaïve will be provided from LIBRETTO-001 and study LIBRETTO-121 as specific obligations (SOBs).

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 5.2 is acceptable.

The CHMP endorsed the Risk Management Plan version 5.3 with the following content:

## Safety concerns

Table 41. List of Safety Concerns

| List of Safety Concerns    | List of Safety Concerns                                                                                                                            |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks | None                                                                                                                                               |
| Important potential risks  | Liver injury Cardiac arrhythmia due to QT prolongation Reproductive and developmental toxicities Growth plate abnormalities in paediatric patients |
| Missing information        | Exposure and safety in patients with severe hepatic impairment Exposure and safety in patients with cardiac impairment                             |

The existing list of safety concerns remain unchanged,

## Pharmacovigilance plan

Routine pharmacovigilance activities remained sufficient to characterise the risks of the product in all approved indications.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 42. Part V.2.- Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                    | Risk Minimisation Measures                                                                                           | Pharmacovigilance Activities                                                                                                                                                                     |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Liver injury                                      | Routine risk minimisation measures: SmPC Sections 4.2 and 4.4. Additional risk minimisation measures: Not applicable | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Study: None                                        |
| Cardiac arrhythmia due to QT prolongation         | Routine risk minimisation measures: SmPC Sections 4.2 and 4.4. Additional risk minimisation measures: Not applicable | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Study: None                                        |
| Reproductive and developmental toxicity           | Routine risk minimisation measures: SmPC Section 4.6 Additional risk minimisation measures: Not applicable           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Pregnancy and Breastfeeding follow-up forms Additional pharmacovigilance activities: Study: None |
| Growth plate abnormalities in paediatric patients | Routine risk minimisation measures: SmPC Sections 4.2 and 5.3 Additional risk minimisation measures: Not applicable  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Study: None                                        |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                 | Risk Minimisation Measures                                                                                                                                                                                                                                                               | Pharmacovigilance Activities                                                                                                                              |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Exposure and safety in patients with severe hepatic impairment | Routine risk minimisation measures: A clinical pharmacology study assessing the effect of hepatic impairment on the pharmacokinetics of selpercatinib is completed. SmPC is updated based on the safety and pharmacokinetics data. Additional risk minimisation measures: Not applicable | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Study: None |
| Exposure and safety in patients with cardiac impairment        | Routine risk minimisation measures: None Additional risk minimisation measures: Not applicable                                                                                                                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Study: None |

Abbreviation: SmPC = Summary of Product Characteristics.

Routine risk minimisation measures remain sufficient to mitigate the risks of selpercatinib in all indications.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2,4,4, 4.8 and 5.1, of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The proposed revisions do not significantly affect the overall readability. It is not considered necessary to conduct consultation with target patient groups further to that performed for the initial MAA.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The agreed indication is:

Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with: advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate)

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

Standard options for patients in first-line with advanced thyroid cancer refractory to iodine include sorafenib and levantinib according to ESMO guidelines. However, no targeted agents are approved as first-line therapy for patients with RET fusion-positive thyroid cancer.

## 3.1.3. Main clinical studies

Clinical efficacy and safety of selpercatinib in treatment of (i) adults with an advanced RET fusionpositive thyroid cancer without prior standard first line therapy, and (ii) adolescents with an advanced RET fusion-positive thyroid cancer (i.e. first and second line) are based on analyses of the interim data from LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121 respectively.

LIBRETTO-001 is a global, multi-cohort, open-label, phase 1/2 study in adult and adolescent patients with advanced RET-altered tumours. The phase 2 portion evaluates efficacy in cohorts based on tumour type, type of RET alteration, and prior treatment. The primary objective was to determine ORR by IRC assessment according to RECIST 1.1. DOR, PFS and OS were secondary endpoints.

LIBRETTO-121 is a multicenter, open-label, Phase 1/2 study in pediatric patients (≥ 12 years of age and ≤  21  years)  with  an  advanced  solid  or  primary  CNS  tumor  harboring  an  activating RET alteration (LIBRETTO-121.

## 3.2. Favourable effects

Of the RET fusion-positive thyroid cancer patients naive to systemic therapy other than radioactive iodine, and enrolled in LIBRETTO-001, 24 patients had the opportunity to be followed for at least 6 months and were considered efficacy eligible.

At the data cut-off of 13 January 2023, 8 more patients were included in the analysis. The data showed an ORR in a total of 24 patients of 95.8% (95%CI: 78.9, 99.9), with 20.8 %(n=5) of the patients with CR, and 75% (n=18) with PR. With a median duration of follow-up of 17.8 months, the DoR was not reached (95% CI: 42.8 months, not estimable).

As of 13 January 2023, 10 patients with RET fusion-positive thyroid cancer aged 12 to   years have been treated in LIBRETTO-121. Of these 10 patients, 8 patients were less than 18 years of age. Of the 10 patients, 4 were previously treated with radioactive iodine only, 2 had received prior systemic therapy that did not include radioactive iodine and 4 were not previously treated with any systemic therapy. For all 10 patients, objective response rate was 60.0% (95% CI: 26.2, 87.8) per IRC. Three (3) patients had confirmed complete response whilst 3 patients had confirmed partial response.

## 3.3. Uncertainties and limitations about favourable effects

The uncertainties and limitations are mainly related to the uncontrolled nature of the pivotal trial which hampers the interpretation of the time-to-event endpoints (PFS, OS).

Contextualisation of the data coming from an uncontrolled study with the results of other systemic therapy (e.g. lenvatinib and sorafenib) is challenging given that response rates observed for selpercatinib have been reported in a selected patient population including only patients with RET fusions, while other medicines have been investigated in unselected patient populations.

<div style=\"page-break-after: always\"></div>

The selected population raises several concerns: progressive disease status at baseline was not a selection criteria, status of having received RAI prior selpercatinib at inclusion was not recorded in a clear manner, and there is a lack of information on screening failure.

The efficacy data are yet mature and longer follow-up is needed.

These remaining limitations will be addressed post authorisation with the submission of updated data and longer follow-up from the studies LIBRETTO-001 and LIBRETTO-121 (SOBs).

## 3.4. Unfavourable effects

Safety data assessed in the current procedure are available from a total of 796 patients  the LIBRETTO001  study.  The  safety  data  from  837  patients  reflected  in  the  SmPC  were  assessed  in  procedure EMEA/H/C/005375/R/0026 concluded on 05/01/2024.

Safety  was  evaluated  in  patients  in  the  Overall  Safety  Population  (N=796)  and  in  the  TC  Safety Population (N=54) who received at least 1 dose of selpercatinib as of the data cut-off date of 15 June 2021.

In terms of exposure, the median time on treatment was 21.29 and 20.2 months, respectively, for the Overall Safety Population and TC Safety Population. In the Treatment-Naïve Patients (not previously treated with systemic therapy other than RAI - TC: TrtSysNaïve patients) (n=18), the median treatment duration is 22.3 months (range: 0.4 to 35.6 months) and 86.2% of patients were on treatment for at least 24 months.

The most frequent TEAEs (any grade) occurring 30% or more in the TC: TrtSysNaïve (Safety) were abdominal pain, rash, headache, and lymphopaenia.

The  most  frequent  Grade  3  or  higher  TEAEs  reported  in  5%  or  more  of  patients  in  both  the TC:  TrtSysNaïve  (Safety)  patients  and  Overall  Safety  Population  were  hypertension,  lymphopaenia hyponatraemia, ALT increased, AST increased, and diarrhoea.

The most common treatment-emergent serious adverse events (TE-SAEs) occurring in ≥2% of patients in the TC Safety Populations were abdominal pain, pneumonia, sepsis, vomiting and pyrexia.

The most common treatment-emergent serious adverse events (TE-SAEs) occurring in ≥2% of patients in the TC: TrtSysNaïve Population were abdominal pain, sepsis, respiratory failure, vomiting, cardiac failure, diverticulitis, cholestasis, hepatic haemorrhage, and lymphopaenia.

In TC: TrtSysNaïve Population, there was 1 death in total that occurred more than 28 days after the final dose of selpercatinib due to disease progression. No patients experienced a fatal (Grade 5) TEAE.

The adverse events of special interest (AESIs) analysed did not change compared to those reported previously.

## 3.5. Uncertainties and limitations about unfavourable effects

No adolescent patients are present from the ongoing pivotal study LIBRETTO-001 in the advanced RET fusion-positive TC population and data from study LIBRETTO-121 are limited to 10 paedatric patients. Data in  adults  are  limited  to  24  patients.  Data  on  long-term  safety  in  adult  and  adolescent  will  be provided from LIBRETTO-001 and study LIBRETTO-121 as specific obligations (SOBs).

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 37.  Effects Table for selpercatinib for the Treatment adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer in the first-line setting (data cut-off: 15 June 2021 and 13 January 2023)

| Effect                                                      | Effect                                                      | Short descripti on                                          | Unit                                                        | Treat ment Cont rol                                         | Uncertainti es / Strength of evidence                       | Referen ces                                                 |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Favourable Effects                                          | Favourable Effects                                          |                                                             |                                                             |                                                             |                                                             |                                                             |
| Treatament of TCTrtSysNaïve (n=24) Cut-off date 13 Jan 2023 | Treatament of TCTrtSysNaïve (n=24) Cut-off date 13 Jan 2023 | Treatament of TCTrtSysNaïve (n=24) Cut-off date 13 Jan 2023 | Treatament of TCTrtSysNaïve (n=24) Cut-off date 13 Jan 2023 | Treatament of TCTrtSysNaïve (n=24) Cut-off date 13 Jan 2023 | Treatament of TCTrtSysNaïve (n=24) Cut-off date 13 Jan 2023 | Treatament of TCTrtSysNaïve (n=24) Cut-off date 13 Jan 2023 |
| ORR                                                         | Rate                                                        | % (95% CI)                                                  | 95.8 (78.9, 99.9)                                           | NA                                                          | - Absence of comparative data -                             | LIBRETT O-001                                               |
| DoR                                                         | Median                                                      | Months (95% CI)                                             | NE (42.8, NE)                                               | NA                                                          | - Absence of comparative data -                             | LIBRETT O-001                                               |
| Cut-off date 15 June 2021                                   | Cut-off date 15 June 2021                                   |                                                             |                                                             |                                                             |                                                             |                                                             |
| TTR                                                         | Median                                                      | Months (25 th , 75 th perc.)                                | 1.8 (1.8, 4.6)                                              | NA                                                          |                                                             |                                                             |
| TTBR                                                        | Median                                                      | Months (25 th , 75 th perc.)                                | 3.6 (1.7- 13.8)                                             | NA                                                          |                                                             |                                                             |
| PFS                                                         | Median                                                      | Months (95% CI)                                             | NE (19.3, NE)                                               | NA                                                          |                                                             |                                                             |
| OS                                                          | Median                                                      | Months (95% CI)                                             | NE (NE, NE)                                                 | NA                                                          |                                                             |                                                             |
| Unfavourable Effects TCTrtSysNaïve (n=24)                   | Unfavourable Effects TCTrtSysNaïve (n=24)                   |                                                             |                                                             |                                                             |                                                             |                                                             |
| AEs grade ≥3                                                | Adverse events grade 3-4 regardless causality               | %                                                           | 55.6%                                                       | NA                                                          | Uncontrolled data                                           |                                                             |
| AEs grade ≥3                                                | Serious AEs regardless causality                            | %                                                           | 22.2%                                                       | NA                                                          | Uncontrolled data                                           |                                                             |
| Deaths                                                      | Number of deaths                                            | Absolu te value (%)                                         | % (n=0)                                                     | NA                                                          | Uncontrolled data                                           |                                                             |
| QT prolongation                                             | AE of special interest                                      | %                                                           | 22.2%                                                       | NA                                                          | Uncontrolled data                                           |                                                             |
| AST increased                                               | AE of special interest                                      | %                                                           | 11.1%                                                       | NA                                                          | Uncontrolled data                                           |                                                             |
| ALT increased                                               | AE of special interest                                      | %                                                           | 16.7%                                                       | NA                                                          | Uncontrolled data                                           |                                                             |

Abbreviations:  Abbreviations:  CSR=Clinical  study  report,  HR=Hazard  ratio,  NA=not  applicable,  ORR=Objective response rate, OS=Overall survival, PFS=Progression-free survival.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Data supporting this application for selpercatinib as monotherapy for adults with advanced RET fusionpositive thyroid cancer without prior standard first line therapy (i.e. first-line setting), is based on a single-arm study LIBRETTO-001, which remains largely exploratory and make interpretation of time to event endpoints and any potential long-term benefit challenging.

Nevertheless, this approach is acceptable in the context of a CMA for a product intended for a patient population with high unmet medical need when the observed ORR is outstanding and durable.

<div style=\"page-break-after: always\"></div>

The obtained ORR of 95.8 % is considered meaningful in patients with RET- fusion-positive TC in firstline setting.

Median DOR was not reached at a median follow-up time of 17.8 months and rate of patients with duration response at 12 and 24 months suggest lasting benefits from treatment with selpercantinib.

Other approved front-line therapies with established benefit are approved, and an indirect comparison could not be performed due to the specificity of selpercatinib molecular target. The activity of selpercatinib is however considered compelling.

The safety profile observed in the data from the 15 June 2021 cut-off  and data from 13 June 2023 cutoff submitted in the context of the parallel procedure EMEA/H/C/005375/R/0026 remains consistent with previously reported data. No new ADRs or AESIs have been identified since initial authorisation and the safety profile is consistent between the Treatment-Naïve Patients and the Overall Safety Population.

To support the extension of indication in adolescent 12 years of age and older with advanced RET fusion-positive thyroid cancer data from study LIBRETTO-121 have been provided.  Even though the efficacy results from LIBRETTO-121 were lower than anticipated with an ORR of 60.0% (95% CI: 26.2, 87.8), the ORR remains positive and promising. Additional Efficacy and Safety Data from LIBRETTO-001 and LIBRETTO-121 Studies will be provided to address remaining uncertainties.

## 3.7.2. Balance of benefits and risks

The provided results from LIBRETTO-001 and LIBRETTO-121 have shown activity in term of tumour shrinkage. Responses appear durable and the safety profile is consistent with that reported previously.

In view of the remaining uncertainties related to the limited data set and duration of follow-up, final efficacy and safety data are required as confirmatory evidence (SOBs).

## 3.7.3. Additional considerations on the benefit-risk balance

As comprehensive data on the product are not available in the first-line treatment of RET- fusionpositive TC, a conditional marketing authorisation was requested by the applicant for this extension of indication. The new indication for this product falls within the scope of Article 14-a of Regulation (EC) No 726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a lifethreatening disease.

Furthermore, the CHMP considers that the product fulfils the requirements for a conditional marketing authorisation:

- The benefit-risk balance is positive, as discussed above.
- It is likely that the applicant will be able to provide comprehensive data. The applicant will provide final efficacy and safety data with longer follow-up for both the adults and paediatric patient populations. Results are expected with LIBRETTO-001 study, Cohort 2 by December 2025 for the adult population and with LIBRETTO-121 study by June 2025 for the paediatric population.
- Unmet medical need will be addressed. One factor preventing inter-study comparison with other MKIs is the difference between patient populations. Indeed, response observed in selpercatinib have been observed in a population including only patients with RET fusions, while other approved medicines in TC have been investigated in an unselected patient population. The missing information is relative sensitivity of patients with tumours harbouring

<div style=\"page-break-after: always\"></div>

RET fusion to MKIs (lenvatinib and sorafenib) when compared to unselected patients. The MKI with the higher estimated ORR is lenvatinib with 65% (95% CI: 59.0; 71.0). Considering that the ORR of selpercatinib in this selected patient population is outstanding with 95.8% (95% CI: 78.9, 99.9), it is unlikely that the RET TC naïve patients treated with Lenvatinib or sorafenib would experience a dramatically higher response rate compared to the unselected patients. Altogether, it is considered that a major therapeutic advantage over the existing authorised medicinal products in the overlapping indication is demonstrated.

- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. Given the positive benefit/risk and the unmet medical need in the applied indication as described above, this is considered fulfilled.

## 3.8. Conclusions

The overall B/R of Retsevmo for the first line treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) is positive subject to the specific obligations and conditions imposed in order to inform the long-term efficacy and safety profile of the product in this new indication.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II, and IIIB    |

Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer in the first-line setting for RETSEVMO based on interim data from studies LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121; LIBRETTO-001 is an openlabel, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumors. LIBRETTO-121 is a Phase 1/2 study of selpercatinib in paediatric patients with advanced RETaltered solid or primary central nervous system tumours. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.3 of the RMP has been agreed.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, II and IIIB and to the Risk Management Plan are recommended.

<div style=\"page-break-after: always\"></div>

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Retsevmo is not similar to Sorafenib within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, II and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                  | Due date         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with RET fusion-positive thyroid cancer, the MAH should submit the final data from the study LIBRETTO-121.                                                 | 30 June 2025     |
| In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with systemic treatment naïve RET fusion-positive thyroid cancer, the MAH should submit the final data from the cohort 2 of the pivotal study LIBRETTO-001 | 31 December 2025 |